

Volume 8, issue 1, December 2016

133 articles in this issue

Volume 8, Issue 1, December 2016

ISSN: 1868-7075 (Print) 1868-7083 (Online)

In this issue (133 articles)

Page 1 of 7

1. Research

Topical Collection

[Promoter hypermethylation of *SHOX2* and *SEPT9* is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract](#)

V. Branchi, P. Schaefer, A. Semaan, A. Kania, P. Lingohr...Article:133

[Download PDF \(687KB\)](#) [View Article](#)

2. Research

Topical Collection

[Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance](#)

Michaël Van Damme, Emerence Cromptot, Nathalie Meuleman...Article:132

[Download PDF \(1827KB\)](#) [View Article](#)

3. Research

Topical Collection

[Epigenome-wide association data implicates DNA methylation-mediated genetic risk in psoriasis](#)

Fusheng Zhou, Changbing Shen, Jingkai Xu, Jing Gao, Xiaodong Zheng...Article:131

[Download PDF \(1520KB\)](#) [View Article](#)

4. Short report

Topical Collection

[A methylation PCR method determines *FMR1* activation ratios and differentiates premutation allele mosaicism in carrier siblings](#)

Andrew G. Hadd, Stela Filipovic-Sadic, Lili Zhou, Arianna Williams...Article:130

[Download PDF \(972KB\)](#) [View Article](#)

5. Research

Topical Collection

[Aberrant DNA hypermethylation-silenced *SOX21-AS1* gene expression and its clinical importance in oral cancer](#)

Cheng-Mei Yang, Tsung-Han Wang, Hung-Chih Chen, Sung-Chou Li...Article:129

[Download PDF \(2362KB\)](#) [View Article](#)

6. Short report

Topical Collection

[Assessment of global DNA methylation in the first trimester fetal tissues exposed to maternal cigarette smoking](#)

Svetlana Fa, Trine Vilsbøll Larsen, Katrine Bilde, Tina F. Daugaard...Article:128

[Download PDF \(903KB\)](#) [View Article](#)

7. Research

Topical Collection

[Smoking-associated DNA methylation markers predict lung cancer incidence](#)

Yan Zhang, Magdeldin Elgizouli, Ben Schöttker, Bernd Holleczeck...Article:127

[Download PDF \(1804KB\)](#) [View Article](#)

8. Research

Topical Collection

[Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5'-monophosphate response element modulator alpha in systemic lupus erythematosus](#)

Qing Zhang, Shu Ding, Huilin Zhang, Hai Long, Haijing Wu, Ming Zhao...Article:126

[Download PDF \(2034KB\)](#) [View Article](#)

9. Research

[Topical Collection](#)

[Augmentation of histone deacetylase 3 \(HDAC3\) epigenetic signature at the interface of proinflammation and insulin resistance in patients with type 2 diabetes](#)

Chandrakumar Sathishkumar, Paramasivam Prabu, Mahalingam Balakumar...Article:125

[Download PDF \(904KB\)](#) [View Article](#)

10. Research

[Topical Collection](#)

[Mendelian inheritance of trimodal CpG methylation sites suggests distal cis-acting genetic effects](#)

Shaza B. Zaghlool, Mashael Al-Shafaj, Wadha A. Al Muftah...Article:124

[Download PDF \(1110KB\)](#) [View Article](#)

11. Research

[Topical Collection](#)

[cPAS-based sequencing on the BGISEQ-500 to explore small non-coding RNAs](#)

Tobias Fehlmann, Stefanie Reinheimer, Chunyu Geng, Xiaoshan Su...Article:123

[Download PDF \(3459KB\)](#) [View Article](#)

12. Review

[Topical Collection](#)

[Genome-wide epigenomic profiling for biomarker discovery](#)

René A. M. Dirks, Hendrik G. Stunnenberg, Hendrik Marks...Article:122

[Download PDF \(1087KB\)](#) [View Article](#)

13. Erratum

[Erratum to: Donor age and C1orf132/MIR29B2C determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation](#)

Mağdalena Spólnicka, Renata Zbieć Piekarska, Emilia Jaskuła...Article:121

[Download PDF \(236KB\)](#) [View Article](#)

14. Research

[Topical Collection](#)

[In epithelial cancers, aberrant COL17A1 promoter methylation predicts its misexpression and increased invasion](#)

Pulari U. Thangavelu, Tibor Krenács, Eloise Dray...Article:120

[Download PDF \(2529KB\)](#) [View Article](#)

15. Review

[Topical Collection](#)

[The quest for an effective and safe personalized cell therapy using epigenetic tools](#)

T. A. L. Brevini, G. Pennarossa, E. F. M. Manzoni, C. E. Gandolfi...Article:119

[Download PDF \(682KB\)](#) [View Article](#)

16. Research

[Topical Collection](#)

[Birth weight-for-gestational age is associated with DNA methylation at birth and in childhood](#)

Golareh Agha, Hanine Hajj, Sheryl L. Rifas-Shiman, Allan C. Just...Article:118

[Download PDF \(1250KB\)](#) [View Article](#)

17. Research

[Topical Collection](#)

[Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma](#)

Stine Dam Henriksen, Poul Henning Madsen, Anders Christian Larsen...Article:117

[Download PDF \(1150KB\)](#) [View Article](#)

18. Research

[Topical Collection](#)

[Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation](#)

Karin Boer, L. Elly A. de Wit, Fleur S. Peters, Dennis A. Hesselink...Article:116

[Download PDF \(1560KB\)](#) [View Article](#)

19. Review

[Topical Collection](#)

[Blood-based DNA methylation as biomarker for breast cancer: a systematic review](#)

Qiuqiong Tang, Jie Cheng, Xue Cao, Harald Surowy, Barbara Burwinkel...Article:115

[Download PDF \(869KB\)](#) [View Article](#)

20. Research

[Topical Collection](#)

[Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial](#)

Susan J. van Dijk, Jing Zhou, Timothy J. Peters, Michael Buckley...Article:114

[Download PDF \(1590KB\)](#) [View Article](#)

21. [Discovery and replication of a peripheral tissue DNA methylation biosignature to augment a suicide prediction model](#)

Makena L. Clive, Marco P. Boks, Christiaan H. Vinkers...Article:113

[Download PDF \(814KB\)](#) [View Article](#)

22. Short report

[Topical Collection](#)

[Narrowing the *FOXF1* distant enhancer region on 16q24.1 critical for ACDMPV](#)

Przemyslaw Szafranski, Carmen Herrera, Lori A. Proe...Article:112

[Download PDF \(1561KB\)](#) [View Article](#)

23. Research

[Topical Collection](#)

[Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use](#)

Andrew M. Kaz, Chao-Jen Wong, Vinay Varadan, Joseph E. Willis...Article:111

[Download PDF \(3636KB\)](#) [View Article](#)

24. Research

[Topical Collection](#)

[Intra-individual changes in DNA methylation not mediated by cell-type composition are correlated with aging during childhood](#)

Kristina Gervin, Bettina Kulle Andreassen, Hanne Sagsveen Hjorthaug...Article:110

[Download PDF \(1647KB\)](#) [View Article](#)

25. Research

[Topical Collection](#)

[Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection](#)

Yun Su, HongBin Fang, Feng JiangArticle:109

[Download PDF \(543KB\)](#) [View Article](#)

26. Research

[Methylome analysis for spina bifida shows *SOX18* hypomethylation as a risk factor with evidence for a complex \(epi\)genetic interplay to affect neural tube development](#)

Anne Roctus, Raf Winand, Griet Laenen, Elise Vangeel...Article:108

[Download PDF \(1758KB\)](#) [View Article](#)

27. Research

[Topical Collection](#)

[Maternal vitamin D depletion alters DNA methylation at imprinted loci in multiple generations](#)

Jing Xue, Sarah A. Schoenrock, William Valdar, Lisa M. Tarantino...Article:107

[Download PDF \(1867KB\)](#) [View Article](#)

28. Research

[Topical Collection](#)

[Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL](#)

Santhilal Subhash, Per-Ola Andersson, Subazini Thankaswamy Kosalaj...Article:106

[Download PDF \(1451KB\)](#) [View Article](#)

29. Review

[Topical Collection](#)

[Epigenetic polypharmacology: from combination therapy to multitargeted drugs](#)

Angel R. de Lera, A. GanesanArticle:105

[Download PDF \(2794KB\)](#) [View Article](#)

30. Research

[Topical Collection](#)

[*PITX3* promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy](#)

Emily Eva Holmes, Diane Goltz, Verena Sailer, Maria Jung...Article:104

[Download PDF \(1614KB\)](#) [View Article](#)

31. Research

[Topical Collection](#)

[DNA methylation and smoking in Korean adults: epigenome-wide association study](#)

Mi Kyeong Lee, Yoonki Hong, Sun-Young Kim, Stephanie J. London...Article:103

[Download PDF \(576KB\)](#) [View Article](#)

32. Review

[Topical Collection](#)

[The emerging role of lysine methyltransferase SETD8 in human diseases](#)

Ciro Milite, Alessandra Feoli, Monica Viviano, Donatella Rescigno...Article:102

[Download PDF \(1665KB\)](#) [View Article](#)

33. Methodology

[Topical Collection](#)

[MSP-HTPrimer: a high-throughput primer design tool to improve assay design for DNA methylation analysis in epigenetics](#)

Ram Vinay Pandey, Walter Pulverer, Rainer Kallmeyer...Article:101

[Download PDF \(1409KB\)](#) [View Article](#)

34. Research

[Topical Collection](#)

[SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas](#)

Alexander Semaan, Anne van Ellen, Sebastian Meller...Article:100

[Download PDF \(878KB\)](#) [View Article](#)

35. Research

[Topical Collection](#)

[Neonatal monocytes exhibit a unique histone modification landscape](#)

Jennifer R. Bermick, Nathalie J. Lambrecht, Aaron D. denDekker...Article:99

[Download PDF \(2266KB\)](#) [View Article](#)

36. Review

[Topical Collection](#)

[Epigenetic modulators as therapeutic targets in prostate cancer](#)

Inês Graça, Eva Pereira-Silva, Rui Henrique, Graham Packham...Article:98

[Download PDF \(2048KB\)](#) [View Article](#)

37. Research

[Topical Collection](#)

[Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy](#)

Milan S. Geybels, Jonathan L. Wright, Marina Bibikova...Article:97

[Download PDF \(1463KB\)](#) [View Article](#)

38. Research

[Topical Collection](#)

[Molecular Pap smear: HPV genotype and DNA methylation of *ADCY8*, *CDH8*, and *ZNF582* as an integrated biomarker for high-grade cervical cytology](#)

Jane Shen-Gunther, Chiou-Miin Wang, Graham M. Poage, Chun-Lin Lin...Article:96

[Download PDF \(2253KB\)](#) [View Article](#)

39. Research

[Topical Collection](#)

[Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma](#)

Lasse Sommer Kristensen, Jakob Werner Hansen...Article:95

[Download PDF \(1826KB\)](#) [View Article](#)

40. Review

[Topical Collection](#)

[Antidepressant medication during pregnancy and epigenetic changes in umbilical cord blood: a systematic review](#)

Anne-Cathrine F. Viuff, Lars Henning Pedersen, Kasper Kyng...Article:94

[Download PDF \(541KB\)](#) [View Article](#)

41. Letter to the Editor

[Topical Collection](#)

[Donor age and *C1orf132/MIR29B2C* determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation](#)

Magdalena Spólnicka, Renata Zbieć Piekarska, Emilia Jaskuła...Article:93

[Download PDF \(938KB\)](#) [View Article](#)

42. Review

[Topical Collection](#)

[DNA methylation: conducting the orchestra from exposure to phenotype?](#)

Fleur A. D. Leenen, Claude P. Muller, Jonathan D. Turner...Article:92

[Download PDF \(1307KB\)](#) [View Article](#)

43. Short report

[Topical Collection](#)

[Identification of a methylation profile for *DNMT1*-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy](#)

Kristin D. Kernohan, Laila Cigana Schenkel, Lijia Huang...Article:91

[Download PDF \(2182KB\)](#) [View Article](#)

44. Short report

[Topical Collection](#)

[DNA methylation at birth within the promoter of ANRIL predicts markers of cardiovascular risk at 9 years](#)

Robert Murray, Jennifer Bryant, Phil Titcombe, Sheila J. Barton...Article:90

[Download PDF \(445KB\)](#) [View Article](#)

45. Research

[Topical Collection](#)

[DNA methylation and gene expression of *HIF3A*: cross-tissue validation and associations with BMI and insulin resistance](#)

Ailsa Maria Main, Linn Gillberg, Anna Louisa Jacobsen, Emma Nilsson...Article:89

[Download PDF \(562KB\)](#) [View Article](#)

46. Research

[Topical Collection](#)

[p38-MAPK/MSK1-mediated overexpression of histone H3 serine 10 phosphorylation defines distance-dependent prognostic value of negative resection margin in gastric cancer](#)

Shafqat Ali Khan, Ramchandra Amnekar, Bharat Khade...Article:88

[Download PDF \(2257KB\)](#) [View Article](#)

47. Research

[Topical Collection](#)

[Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells](#)

Katherine A. Sanders, Miles C. Benton, Rod A. Lea, Vicki E. Maltby...Article:87

[Download PDF \(712KB\)](#) [View Article](#)

48. Short report

[Topical Collection](#)

[Epigenetic features of *FoxP3* in children with cow's milk allergy](#)

Lorella Paparo, Rita Nocerino, Linda Cosenza, Rosita Aitoro...Article:86

[Download PDF \(716KB\)](#) [View Article](#)

49. Research

[Topical Collection](#)

[Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis](#)

Jiajin Yang, Heng Ge, Caroline J. Poulton, Susan L. Hogan...Article:85

[Download PDF \(2635KB\)](#) [View Article](#)

50. Erratum

[Erratum to: MSRE-HTPrimer: a high-throughput and genome-wide primer design pipeline optimized for epigenetic research](#)

Ram Vinay Pandey, Walter Pulverer, Rainer Kallmeyer...Article:84

[Download PDF \(336KB\)](#) [View Article](#)

51. Research

[Topical Collection](#)

[Tobacco smoking differently influences cell types of the innate and adaptive immune system—indications from CpG site methylation](#)

Mario Bauer, Beate Fink, Loreen Thürmann, Markus Eszlinger...Article:83

[Download PDF \(1292KB\)](#) [View Article](#)

52. Research

[Topical Collection](#)

[Increased global placental DNA methylation levels are associated with gestational diabetes](#)

C. Reichetzeder, S. E. Dwi Putra, T. Pfab, T. Slowinski, C. Neuber...Article:82

[Download PDF \(640KB\)](#) [View Article](#)

53. Research

[Topical Collection](#)

[Genome-wide DNA methylation profiling with MeDIP-seq using archived dried blood spots](#)

Nicklas H. Staunstrup, Anna Starnawska, Mette Nyegaard...Article:81

[Download PDF \(2015KB\)](#) [View Article](#)

54. Research

[Topical Collection](#)

[Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma](#)

Pierre L. Triozzi, Susan Achberger, Wayne Aldrich, John W. Crabb...Article:80

[Download PDF \(522KB\)](#) [View Article](#)

55. Research

[Topical Collection](#)

[Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients](#)

Benet Pera, Tiffany Tang, Rossella Marullo, Shao-Ning Yang...Article:79

[Download PDF \(2807KB\)](#) [View Article](#)

56. Review

[Topical Collection](#)

[Genetic and epigenetic mechanisms in the development of arteriovenous malformations in the brain](#)

Jaya Mary Thomas, Sumi Surendran, Mathew Abraham, Arumugam Rajavelu...Article:78

[Download PDF \(970KB\)](#) [View Article](#)

57. Research

[Topical Collection](#)

[Next-generation sequencing methylation profiling of subjects with obesity identifies novel gene changes](#)

Samantha E. Day, Richard L. Coletta, Joon Young Kim...Article:77

[Download PDF \(658KB\)](#) [View Article](#)

58. Review

[Topical Collection](#)

[Studying epigenetic complexes and their inhibitors with the proteomics toolbox](#)

David Weigt, Carsten Hopf, Guillaume Médard...Article:76

[Download PDF \(993KB\)](#) [View Article](#)

59. Methodology

[Topical Collection](#)

[Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses](#)

Emma Cazaly, Russell Thomson, James R. Marthick, Adele F. Holloway...Article:75

[Download PDF \(2172KB\)](#) [View Article](#)

60. Research

[Topical Collection](#)

[Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas](#)

Annette M. Lim, Nicholas C. Wong, Ruth Pidsley, Elena Zotenko...Article:74

[Download PDF \(870KB\)](#) [View Article](#)

61. Research

[Topical Collection](#)

[Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment](#)

Julia Krushkal, Yingdong Zhao, Curtis Hose, Anne Monks...Article:73

[Download PDF \(1800KB\)](#) [View Article](#)

62. Research

[Topical Collection](#)

[PPARGC1 \$\alpha\$ gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns](#)

Sandra Côté, Valérie Gagné-Ouellet, Simon-Pierre Guay...Article:72

[Download PDF \(1003KB\)](#) [View Article](#)

63. Review

[Topical Collection](#)

[A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers](#)

Jeannine Diesch, Anabel Zwick, Anne-Kathrin Garz, Anna Palau...Article:71

[Download PDF](#) (578KB) [View Article](#)

64. Research

[Topical Collection](#)

[Genome-wide placental DNA methylation analysis of severely growth-discordant monochorionic twins reveals novel epigenetic targets for intrauterine growth restriction](#)

Maian Roifman, Sanaa Choufani, Andrei L. Turinsky, Sascha Drewlo...Article:70

[Download PDF](#) (2245KB) [View Article](#)

65. Short report

[Topical Collection](#)

[Two maternal duplications involving the *CDKN1C* gene are associated with contrasting growth phenotypes](#)

Susanne Eriksen Boonen, Andrea Freschi, Rikke Christensen...Article:69

[Download PDF](#) (1513KB) [View Article](#)

66. Review

[Topical Collection](#)

[Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials](#)

Seongseok Yun, Nicole D. Vincelette, Ivo Abraham...Article:68

[Download PDF](#) (944KB) [View Article](#)

67. Research

[Topical Collection](#)

[Amnion as a surrogate tissue reporter of the effects of maternal preeclampsia on the fetus](#)

Masako Suzuki, Ryo Maekawa, Nicole E. Patterson, David M. Reynolds...Article:67

[Download PDF](#) (846KB) [View Article](#)

68. Case study

[Topical Collection](#)

[Combined clinical and genetic testing algorithm for cervical cancer diagnosis](#)

Yu-Ligh Liou, Tao-Lan Zhang, Tian Yan, Ching-Tung Yeh, Ya-Nan Kang...Article:66

[Download PDF](#) (657KB) [View Article](#)

69. Research

[Topical Collection](#)

[Peripheral blood methylation profiling of female Crohn's disease patients](#)

Andrew Y. F. Li Yim, Nicolette W. Duijvis, Jing Zhao...Article:65

[Download PDF](#) (1337KB) [View Article](#)

70. Research

[Topical Collection](#)

[Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort](#)

Laura Perna, Yan Zhang, Ute Mons, Bernd Holleczeck, Kai-Uwe Saum...Article:64

[Download PDF \(584KB\)](#) [View Article](#)

71. Erratum

[Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer](#)

Yang Gao, Allison Jones, Peter A. Fasching, Matthias Ruebner...Article:63

[Download PDF \(339KB\)](#) [View Article](#)

72. Research

[Topical Collection](#)

[Ultraviolet-B induces ERCC6 repression in lens epithelium cells of age-related nuclear cataract through coordinated DNA hypermethylation and histone deacetylation](#)

Yong Wang, Fei Li, Guowei Zhang, Lihua Kang, Huaijin GuanArticle:62

[Download PDF \(2866KB\)](#) [View Article](#)

73. Review

[Topical Collection](#)

[Sirtuin functions and modulation: from chemistry to the clinic](#)

Vincenzo Carafa, Dante Rotili, Mariantonietta Forgione...Article:61

[Download PDF \(1317KB\)](#) [View Article](#)

74. Methodology

[Topical Collection](#)

[Disagreement between two common biomarkers of global DNA methylation](#)

Claudia Knothe, Hiromi Shiratori, Eduard Resch, Alfred Ultsch...Article:60

[Download PDF \(1127KB\)](#) [View Article](#)

75. Review

[Topical Collection](#)

[Histone acetyltransferases: challenges in targeting bi-substrate enzymes](#)

Hannah Wapenaar, Frank J. DekkerArticle:59

[Download PDF \(780KB\)](#) [View Article](#)

76. Review

[Topical Collection](#)

[MeCP2 and the enigmatic organization of brain chromatin. Implications for depression and cocaine addiction](#)

Juan AusióArticle:58

[Download PDF \(1299KB\)](#) [View Article](#)

77. Review

[Topical Collection](#)

[Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy](#)

Ludovica Morera, Michael Lübbert, Manfred Jung Article:57

[Download PDF \(1403KB\)](#) [View Article](#)

78. Editorial

[Topical Collection](#)

[Epigenetic drugs: from chemistry via biology to medicine and back](#)

Lucia Altucci, Marianne G. Rots Article:56

[Download PDF \(363KB\)](#) [View Article](#)

79. Review

[Topical Collection](#)

[Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background](#)

Koraljka Gall Trošelj, Renata Novak Kujundzic, Djurdjica Ugarkovic Article:55

[Download PDF \(1657KB\)](#) [View Article](#)

80. Research

[Topical Collection](#)

[DNA methylation mediates the effect of exposure to prenatal maternal stress on cytokine production in children at age 13½ years: Project Ice Storm](#)

Lei Cao-Lei, Franz Veru, Guillaume Elgbeili, Moshe Szyf... Article:54

[Download PDF \(1007KB\)](#) [View Article](#)

81. Research

[Topical Collection](#)

[RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors](#)

Bryan Oronsky, Jan Scicinski, Pedro Cabrales, Andrew Minchinton Article:53

[Download PDF \(3040KB\)](#) [View Article](#)

82. Short report

[Topical Collection](#)

[Hypomethylation of *FAM63B* in bipolar disorder patients](#)

Anna Starnawska, Ditte Demontis, Andrew McQuillin, Niamh L. O'Brien... Article:52

[Download PDF \(516KB\)](#) [View Article](#)

83. Research

[Topical Collection](#)

[Obesity-related DNA methylation at imprinted genes in human sperm: Results from the TIEGER study](#)

Adelheid Soubry, Lisa Guo, Zhiqing Huang, Cathrine Hoyo... Article:51

[Download PDF \(599KB\)](#) [View Article](#)

84. Short report

[Topical Collection](#)

[CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia](#)

Silvia Fluhr, Melanie Boerries, Hauke Busch, Aikaterini Symeonidi...Article:50

[Download PDF \(549KB\)](#) [View Article](#)

85. Research

[Topical Collection](#)

[MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response](#)

Olivier J. Switzeny, Markus Christmann, Mirjam Renovanz, Alf Giese...Article:49

[Download PDF \(1118KB\)](#) [View Article](#)

86. Research

[Topical Collection](#)

[DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease](#)

Müjdat Zeybel, Sezgin Vatansever, Timothy Hardy, Ayşegül Akder Sarı...Article:48

[Download PDF \(1518KB\)](#) [View Article](#)

87. Research

[Topical Collection](#)

[Kaiso mediates human ICR1 methylation maintenance and *H19* transcriptional fine regulation](#)

Florian Bohne, David Langer, Ursula Martiné, Claudia S. Eider...Article:47

[Download PDF \(1781KB\)](#) [View Article](#)

88. Research

[Topical Collection](#)

[Vitamin C enhances epigenetic modifications induced by 5-azacytidine and cell cycle arrest in the hepatocellular carcinoma cell lines HLE and Huh7](#)

Sahar Olsadat Sajadian, Chaturvedula Tripura...Article:46

[Download PDF \(2527KB\)](#) [View Article](#)

89. Review

[Topical Collection](#)

[Establishing an analytic pipeline for genome-wide DNA methylation](#)

Michelle L. Wright, Mikhail G. Dozmorov, Aaron R. Wolen...Article:45

[Download PDF \(611KB\)](#) [View Article](#)

90. Research

[Topical Collection](#)

[Analysis of *RET* promoter CpG island methylation using methylation-specific PCR \(MSP\), pyrosequencing, and methylation-sensitive high-resolution melting \(MS-HRM\): impact on stage II colon cancer patient outcome](#)

Muriel X. G. Draht, Kim M. Smits, Valérie Jooste, Benjamin Tournier...Article:44

[Download PDF \(923KB\)](#) [View Article](#)

91. Review

[Topical Collection](#)

[The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma](#)

Kai Ma, Baoping Cao, Mingzhou GuoArticle:43

[Download PDF \(552KB\)](#) [View Article](#)

92. Research

[Topical Collection](#)

[The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model](#)

Bebeka Gjoksi, Chafik Ghayor, Indranil Bhattacharya...Article:42

[Download PDF \(2629KB\)](#) [View Article](#)

93. Research

[Topical Collection](#)

[Quantitative methylation analysis reveals distinct association between *PAX6* methylation and clinical characteristics with different viral infections in hepatocellular carcinoma](#)

Yu-Lueng Shih, Chih-Chi Kuo, Ming-De Yan, Ya-Wen Lin...Article:41

[Download PDF \(975KB\)](#) [View Article](#)

94. Erratum

[Erratum to: A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver–Russell and Beckwith–Wiedemann syndromes](#)

Silvia Russo, Luciano Calzari, Alessandro Mussa, Ester Mainini...Article:40

[Download PDF \(293KB\)](#) [View Article](#)

95. Letter to the Editor

[Topical Collection](#)

[Defining the criteria for identifying constitutional epimutations](#)

Mathew A. Sloane, Robyn L. Ward, Luke B. HessonArticle:39

[Download PDF \(376KB\)](#) [View Article](#)

96. Research

[Topical Collection](#)

[The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis](#)

Olga Aprelikova, Kenny Chen, Lara H. El Touny...Article:38

[Download PDF \(2962KB\)](#) [View Article](#)

97. Research

[Topical Collection](#)

[TREM2 upregulation correlates with 5-hydroxymethylcytosine enrichment in Alzheimer's disease hippocampus](#)

Naiara Celarain, Javier Sánchez-Ruiz de Gordo...Article:37

[Download PDF \(1142KB\)](#) [View Article](#)

98. Research

[Topical Collection](#)

[Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral *LINE-1* methylation status in stage III colon cancer patients](#)

Duo Chen, Xianyu Wen, Young Seok Song, Ye-Young Rhee, Tae Hun Lee...Article:36

[Download PDF \(987KB\)](#) [View Article](#)

99. Methodology

[Topical Collection](#)

[Detection and monitoring of hypermethylated *RASSF1A* in serum from patients with metastatic breast cancer](#)

Søren Kristiansen, Dorte Nielsen, György Sölétormos...Article:35

[Download PDF \(1427KB\)](#) [View Article](#)

100. Research

[Topical Collection](#)

[Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model](#)

Quan-Yi Zhao, Pin-Ji Lei, Xiaoran Zhang, Jun-Yi Zheng, Hui-Yi Wang...Article:34

[Download PDF \(2687KB\)](#) [View Article](#)

101. Research

[Topical Collection](#)

[Splicing-dependent expression of microRNAs of mirtron origin in human digestive and excretory system cancer cells](#)

Stasė Butkytė, Laurynas Čiupas, Eglė Jakubauskienė, Laurynas Vilys...Article:33

[Download PDF \(839KB\)](#) [View Article](#)

102. Research

[Topical Collection](#)

[Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis](#)

Shivani N. Kamdar, Linh T. Ho, Ken J. Kron, Ruth Isserlin...Article:32

[Download PDF \(3576KB\)](#) [View Article](#)

103. Research

[Topical Collection](#)

[5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma](#)

Elham Barazeghi, Anthony J. Gill, Stan Sidhu, Olov Norlén...Article:31

[Download PDF \(1799KB\)](#) [View Article](#)

104. Research

[Topical Collection](#)

[Genome-wide analysis of DNA methylation and gene expression defines molecular characteristics of Crohn's disease-associated fibrosis](#)

Tammy Sadler, Jeffrey M. Bhasin, Yaomin Xu, Jill Barnholz-Sloan...Article:30

[Download PDF \(1750KB\)](#) [View Article](#)

105. Research

[Topical Collection](#)

[Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3](#)

A. Boers, R. Wang, R. W. van Leeuwen, H. G. Klip, G. H. de Bock...Article:29

[Download PDF \(830KB\)](#) [View Article](#)

106. Research

[Topical Collection](#)

[Hsa-miR-375 is a predictor of local control in early stage breast cancer](#)

Franz Zehentmayr, Cornelia Hauser-Kronberger, Barbara Zellinger...Article:28

[Download PDF \(1043KB\)](#) [View Article](#)

107. Erratum

[Erratum to: Imprinting disorders: a group of congenital disorders with overlapping patterns of molecular changes affecting imprinted loci](#)

Thomas Eggermann, Guiomar Perez de Nanclares, Eamonn R. Maher...Article:27

[Download PDF \(959KB\)](#) [View Article](#)

108. Methodology

[Topical Collection](#)

[MSRE-HTPrimer: a high-throughput and genome-wide primer design pipeline optimized for epigenetic research](#)

Ram Vinay Pandey, Walter Pulverer, Rainer Kallmeyer...Article:26

[Download PDF \(2554KB\)](#) [View Article](#)

109. Review

[Topical Collection](#)

[Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review](#)

Min Jia, Xu Gao, Yan Zhang, Michael Hoffmeister, Hermann Brenner Article:25

[Download PDF \(566KB\)](#) [View Article](#)

110. Research

[Topical Collection](#)

[Diagnostic and prognostic value of *SHOX2* and *SEPT9* DNA methylation and cytology in benign, paramalignant, and malignant ascites](#)

Maria Jung, Svenja Pützer, Heidrun Gevensleben, Sebastian Meller... Article:24

[Download PDF \(1262KB\)](#) [View Article](#)

111. Research

[Topical Collection](#)

[A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver–Russell and Beckwith–Wiedemann syndromes](#)

Silvia Russo, Luciano Calzari, Alessandro Mussa, Ester Mainini... Article:23

[Download PDF \(2057KB\)](#) [View Article](#)

112. Research

[Topical Collection](#)

[Expression of epigenetic machinery genes is sensitive to maternal obesity and weight loss in relation to fetal growth in mice](#)

Polina E. Panchenko, Sarah Voisin, Mélanie Jouin, Luc Jouneau... Article:22

[Download PDF \(1532KB\)](#) [View Article](#)

113. Research

[Topical Collection](#)

[Frailty is associated with the epigenetic clock but not with telomere length in a German cohort](#)

Lutz Philipp Breitling, Kai-Uwe Saum, Laura Perna, Ben Schöttker... Article:21

[Download PDF \(461KB\)](#) [View Article](#)

114. Research

[Topical Collection](#)

[X chromosome-wide analysis identifies DNA methylation sites influenced by cigarette smoking](#)

Daniella Klebaner, Yunfeng Huang, Qin Hui, Jacquelyn Y. Taylor... Article:20

[Download PDF \(1389KB\)](#) [View Article](#)

115. Research

[Topical Collection](#)

[Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals](#)

Kateřina Trejbalov, Denisa Kovarov, Jana Blařkuv...Article:19

[Download PDF](#) (2169KB) [View Article](#)

116. Reviewer acknowledgement

[Reviewer acknowledgement 2016](#)

Ulrich Mahlknecht...Article:18

[Download PDF](#) (297KB) [View Article](#)

117. Research

[Topical Collection](#)

[DNA methylation and hormone receptor status in breast cancer](#)

Elizaveta V. Benevolenskaya, Abul B. M. M. K. Islam, Habibul Ahsan...Article:17

[Download PDF](#) (1220KB) [View Article](#)

118. Research

[Topical Collection](#)

[Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer](#)

Pier-Luc Clermont, Francesco Crea, Yan Ting Chiang, Dong Lin...Article:16

[Download PDF](#) (2101KB) [View Article](#)

119. Research

[Topical Collection](#)

[Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize *FMRI* transcriptional silencing in fragile X syndrome](#)

Sarah Brasa, Arne Mueller, Sebastien Jacquemont, Florian Hahne...Article:15

[Download PDF](#) (4052KB) [View Article](#)

120. Research

[Topical Collection](#)

[H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus](#)

Zhe Zhang, Lihua Shi, Noor Dawany, Judith Kelsen, Michelle A. Petri...Article:14

[Download PDF](#) (1805KB) [View Article](#)

121. Research

[Topical Collection](#)

[Epigenetic associations of type 2 diabetes and BMI in an Arab population](#)

Wadha A. Al Muftah, Mashael Al-Shafai, Shaza B. Zaghlool...Article:13

[Download PDF](#) (830KB) [View Article](#)

122. Research

[Topical Collection](#)

[The cardiovascular and hypothalamus-pituitary-adrenal axis response to stress is controlled by glucocorticoid receptor sequence variants and promoter methylation](#)

Ting Li-Tempel, Mauro F. Larra, Estelle Sandt, Sophie B. Mériaux...Article:12

[Download PDF \(1073KB\)](#) [View Article](#)

123. Research

[Topical Collection](#)

[Insulin-like growth factor axis in pregnancies affected by fetal growth disorders](#)

Aamod R. Nawathe, Mark Christian, Sung Hye Kim, Mark Johnson...Article:11

[Download PDF \(2140KB\)](#) [View Article](#)

124. Research

[Topical Collection](#)

[Genome-wide DNA methylation analysis of pseudohypoparathyroidism patients with GNAS imprinting defects](#)

Anne Rochtus, Alejandro Martin-Trujillo, Benedetta Izzi...Article:10

[Download PDF \(2119KB\)](#) [View Article](#)

125. Letter to the Editor

[Topical Collection](#)

[Loss of nuclear localization of TET2 in colorectal cancer](#)

Yuji Huang, Guanghui Wang, Zhonglin Liang, Yili Yang, Long Cui...Article:9

[Download PDF \(957KB\)](#) [View Article](#)

126. Research

[Topical Collection](#)

[Maternal B vitamins: effects on offspring weight and DNA methylation at genomically imprinted domains](#)

Lauren E. McCullough, Erlene E. Miller, Michelle A. Mendez...Article:8

[Download PDF \(572KB\)](#) [View Article](#)

127. Research

[Topical Collection](#)

[Integrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs](#)

Leonie Roos, Jenny van Dongen, Christopher G. Bell, Andrea Burri...Article:7

[Download PDF \(2345KB\)](#) [View Article](#)

128. Research

[Topical Collection](#)

[Genome- and epigenome-wide association study of hypertriglyceridemic waist in Mexican American families](#)

Manju Mamtani, Hemant Kulkarni, Thomas D. Dyer, Harald H. H. Göring...Article:6

[Download PDF \(958KB\)](#) [View Article](#)

129. Research

[Topical Collection](#)

[DNA methylation in a Scottish family multiply affected by bipolar disorder and major depressive disorder](#)

Rosie May Walker, Andrea Nikie Christoforou, Daniel L. McCartney...Article:5

[Download PDF \(727KB\)](#) [View Article](#)

130. Review

[Epigenetic associations in relation to cardiovascular prevention and therapeutics](#)

Susanne Voelter-MahlknechtArticle:4

[Download PDF \(942KB\)](#) [View Article](#)

131. Research

[Histone acetylation and histone acetyltransferases show significant alterations in human abdominal aortic aneurysm](#)

Yanshuo Han, Fadwa Tanios, Christian Reeps, Jian Zhang...Article:3

[Download PDF \(3578KB\)](#) [View Article](#)

132. Research

[The influence of menstrual cycle and endometriosis on endometrial methylome](#)

Merli Saare, Vijayachitra Modhukur, Marina Suhorutshenko...Article:2

[Download PDF \(1421KB\)](#) [View Article](#)

133. Research

[Topical Collection](#)

[“Monoallelic germline methylation and sequence variant in the promoter of the *RBI* gene: a possible constitutive epimutation in hereditary retinoblastoma”](#)

Guadalupe Quiñonez-Silva, Mercedes Dávalos-Salas...Article:1

[Download PDF \(1412KB\)](#) [View Article](#)

Editorial Board

Editors-in-Chief

Lucia Altucci, *Università degli Studi della Campania, Italy*

Marianne Rots, *University Medical Center Groningen, The Netherlands*

Founding Editor

Ulrich Mahlknecht, *St Lukas Clinic, Solingen, Germany*

Advisory Board

Rui Henrique, *Portuguese Oncology Institute of Porto and Institute of Biomedical Sciences Abel Salazar, University of Porto, Portugal*

Holger Heyn, *National Center for Genomic Analysis, Center for Genomic Regulation (CNAG-CRG), Barcelona Institute of Science and Technology (BIST), Spain*

Jean-Pierre Issa, *Coriell Institute for Medical Research, USA*

Caroline Relton, *University of Bristol, UK*

Hendrik (Henk) G Stunnenberg, *Princess Máxima Center for Pediatric Oncology, Utrecht and Radboud University Nijmegen, The Netherlands*

Saad Z Usmani, *Levin Cancer Institute, University of North Carolina-Chapel Hill, School of Medicine, USA*

Aging and development epigenetics

Section Editor:

Akihiro Umezawa, *National Institute for Child Health and Development, Japan*

Associate Editors:

Koichiro Nishino, *University of Miyazaki, Japan*

Monika Puzianowska-Kuznicka, *Mossakowski Medical Research Centre, Poland*

Wolfgang Wagner, *Aachen University Medical School, Germany*

Allergy, immunology, pathogens and inflammation

Section Editor:

Georges Herbein, *University of Franche-Comté, France*

Associate Editor:

Kari Nadeau, *Stanford University, USA*

Cancer epigenetics and diagnostics

Section Editors:

Maria Berdasco, *Joseph Carreras Leukemia Research Institute (IJC), Spain*
Carmen Jerónimo, *Portuguese Oncology Institute of Porto (IPO Porto) & University of Porto, Portugal*

Associate Editors:

Nita Ahuja, *Yale University, USA*

James M Flanagan, *Imperial College London, UK*

Mario F Fraga, *Nanomaterials and Nanotechnology Center (CINN-CSIC), Health Research Institute of Asturias (ISPSA), Institute of Oncology of Asturias (IUOPA, University of Oviedo), Spain*

Michèle J Hoffmann, *Heinrich-Heine-University Duesseldorf, Germany*

Bozena Kaminska, *Nencki Institute of Experimental Biology, Poland*

Jonathan Licht, *The University of Florida, USA*

Gwen Lomber, *Medical College of Wisconsin, USA*

Arpad Patai, *Semmelweis University, Hungary*

Qian Tao, *The Chinese University of Hong Kong, Hong Kong*

Raul Urrutia, *Genomics Sciences and Precision Medicine Center, Medical College of Wisconsin, USA*

Stefan Wiemann, *German Cancer Research Center-Heidelberg (DKFZ), Germany*

Keishi Yamashita, *Kitasato University, Japan*

Cardiovascular epigenetics

Section Editor:

Ronan Murphy, *Dublin City University, Ireland*

Endocrinology and metabolic epigenetics

Section Editor:

Sam El-Osta, *Monash University, Australia*

Associate Editors:

Charlotte Ling, *Lund University, Sweden*

Richard Saffery, *Murdoch Childrens Research Institute, Australia*

Environmental epigenetics

Section Editor:

Steven Gray, *St James's Hospital, Ireland*

Associate Editor:

Boris Novakovic, *Murdoch Children's Research Institute, Australia*

Epigenetic biomarkers

Section Editor:

Tomasz K Wojdacz, *Pomeranian Medical University, Poland*

Associate Editor:

Dawn L. DeMeo, *Brigham and Women's Hospital/ Harvard Medical School, USA*

John W Holloway, *University of Southampton, UK*

Harold Snieder, *University Medical Center Groningen, The Netherlands*

Andrew Teschendorff, *Chinese Academy of Sciences and Max-Planck Partner Institute for Computational Biology, CAS, China*

Epigenetic technologies

Section Editor:

Jim Davie, *University of Manitoba, Canada*

Associate Editor:

Albert Jeltsch, *University of Stuttgart, Germany*

Epigenetic therapies and clinical trials

Section Editors:

Paola Arimondo, *Centre National de la Recherche Scientifique, Institut Pasteur, France*

Richard Momparker, *University of Montreal, Canada*

Associate Editors:

Nick La Thangue, *University of Oxford, UK*

Antonello Mai, *"Sapienza" Università di Roma, Italy*

Innovative epigenetic therapies

Section Editor:

David Jay Segal, *University of California-Davis, USA*

Lifestyle epigenetics

Section Editor:

Wim Vanden Berghe, *University of Antwerp, Belgium*

Neurology and psychiatry epigenetics

Section Editors:

Jonathan Mill, *University of Exeter and King's College London, UK*

Moshe Szyf, *McGill University, Canada*

Associate Editor:

Riccardo Marioni, *University of Edinburgh, UK*

Jonathan Turner, *Luxembourg Institute of Health, Luxembourg*

Regenerative medicine

Section Editor:

Adele Murrell, *University of Bath, UK*

Associate Editor:

Peter Rugg-Gunn, *The Babraham Institute, University of Cambridge, UK*

Reproductive and transgenerational epigenetics

Section Editor:

Eamonn Maher, *University of Cambridge, UK*

Associate Editor:

Miguel Constanca, *University of Cambridge, UK*

Gavin Kelsey, *The Babraham Institute and Centre for Trophoblast Research, University of Cambridge, UK*

Statisticians

Lingeng Lu, *Yale University, USA*

Harold Snieder, *University Medical Center Groningen, The Netherlands*

Editorial Board

Lorena Aguilar Arnal, *Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México*

Alfonso Baldi, *Università della Campania Luigi Vanvitelli, Italy*

Steven Belinsky, *Lovelace Respiratory Research Institute, USA*

Rosaria Bennedeti, *Università degli Studi della Campania "Luigi Vanvitelli", Italy*

Francesco Bertoni, *Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Switzerland*

Nathalie Bérubé, *Western University, Canada*

Pilar Blancafort, *The Harry Perkins Institute of Medical Research & University of Western Australia, Australia*

Tiziana Bonaldi, *European Institute of Oncology, Italy*

Miguel Branco, *Queen Mary University of London, UK*
Robert Brown, *Imperial College London, UK*
Kyle J Burghardt, *Wayne State University, USA*
Andres Cardenas, *University of California, Berkeley, USA*
Katherine Chiappinelli, *George Washington University, USA*
James Chim, *University of Hong Kong, Hong Kong*
Gianluigi Condorelli, *Humanitas University, Italy*
Rene Cortese, *University of Missouri, USA*
Christos Damaskos, *University of Athens, Greece*
Soner Dogan, *Yeditepe University, Turkey*
Tomas J Ekström, *Karolinska Institutet, Sweden*
Thomas Eggermann, *RWTH Aachen, Germany*
Karl Ekwall, *Karolinska Institutet, Sweden*
Frank O Fackelmayer, *Institute of Molecular Biology and Biotechnology IMBB-Forth, Greece*
Mirco Fanelli, *University of Urbino "Carlo Bo," Italy*
Robert Feil, *CNRS and University of Montpellier, France*
Roger Foo, *Genome Institute of Singapore, Singapore*
François Fuks, *Univerité libre de Bruxelles, Belgium*
Peter Gluckman, *The Liggins Institute of Medical Research, New Zealand*
Joel Gottesfeld, *The Scripps Research Institute, USA*
Monika Hegi, *Lausanne University Hospital, Switzerland*
Ricky Johnstone, *Peter MacCallum Cancer Centre, Australia*
Meaghan Jones, *The University of British Columbia, Canada*
Masayo Kagami, *National Research Institute for Child Health and Development, Japan*
Yutaka Kondo, *Nagoya City University Graduate School of Medical Sciences, Japan*
Ah-Ng Tony Kong, *Rutgers University, USA*
Michele A La Merrill, *University of California-Davis, USA*
Andy Lau, *Shantou University Medical College, China*
Haitao Li, *Tsinghua University, China*
Lili Li, *The Chinese University of Hong Kong, Hong Kong*
Michael Lübbert, *Universitätsklinikum Freiburg, Germany*
Deborah JG Mackay, *Southampton University Hospital, UK*
Joost Martens, *Radboud Institute for Molecular Life Sciences, The Netherlands*
Patrick O McGowan, *University of Toronto, Canada*

Saverio Minucci, *IFOM - IEO, Italy*
David Monk, *Institut d'Investigació Biomèdica Bellvitge, Spain*
Pamela Munster, *University of California, USA*
Clara Nervi, *University of Rome La Sapienza, Italy*
Andreas Neubauer, *Philipps Universität Marburg, Germany*
Stephen Nimer, *University of Miami, USA*
Miina Ollikainen, *University of Helsinki, Finland*
Jan Postberg, *Witten/Herdecke University, Germany*
H Llewelyn Roderick, *KU Leuven, Belgium*
Olivier Rohr, *University of Strasbourg, France*
Paola Scaffidi, *The Francis Crick Institute and UCL Cancer Institute, UK*
Huidong Shi, *Georgia Cancer Center, Medical College of Georgia, Augusta University, USA*
Toshihiro Shioda, *Massachusetts General Hospital Center for Cancer Research and Harvard Medical School, USA*
Gustavo Turecki, *McGill University, Canada*
Toshikazu Ushijima, *National Cancer Center Research Institute, Japan*
Carine Van Lint, *University of Brussels (ULB), Belgium*
Eric Verdin, *J David Gladstone Institutes, USA*
Aleksandar Vojta, *University of Zagreb, Croatia*
Bea Wisman, *University Medical Center Groningen, The Netherlands*
Olaf Witt, *German Cancer Research Center, Germany*
Suowen Xu, *University of Science and Technology of China, China*
Elisabeth Zeisberg, *University Medical Center Göttingen, Germany*
Vlatka Zoldos, *University of Zagreb, Croatia*

[Submit manuscript](#)

- [Editorial Board](#)
 - [Instructions for Editors](#)
-
- [Sign up for article alerts and news from this journal](#)

Follow

- [Follow us on Facebook](#)

• **ISSN: 1868-7083 (electronic)**

Advertisement

Clinical Epigenetics



KO cell lines

KO cell lines are utile for studying the function of genes and for molecule screening.

invivogen.com

OPEN

Clinical Epigenetics

COUNTRY

Germany

 Universities and research institutions in Germany

SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology
 Developmental Biology
 Genetics
 Molecular Biology

Medicine
 Genetics (clinical)

PUBLISHER

BioMed Central Ltd.

H-INDEX

45

KO cell lines

Gene-modified cell lines

KO cell lines are utile for studying the of genes and for molecule screening.

invivogen.com

OPEN

PUBLICATION TYPE

Journals

ISSN

18687083, 18687075

COVERAGE

2010-2020

INFORMATION

[Homepage](#)
[How to publish in this journal](#)

Call For Papers Elsevier G

Peer Reviewed Indexed Journal
 Collaboration proposals are invited to p
 single platform for worldwide research
 turcomat.org

OPEN

SCOPE

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections: Aging and development epigenetics Allergy, immunology, and pathogen epigenetics Cancer epigenetics and diagnostics Cardiovascular epigenetics Endocrinology and metabolic epigenetics Environmental epigenetics Epigenetic biomarkers Epigenetic technologies Epigenetic drugs and clinical trials Innovative therapies Lifestyle epigenetics Neurology and psychiatry epigenetics Regenerative medicine Reproductive and transgenerational epigenetics

 Join the conversation about this journal

RESEARCH

Open Access



Increased global placental DNA methylation levels are associated with gestational diabetes

C. Reichetzeder^{2,4†}, S. E. Dwi Putra^{1,5†}, T. Pfab^{4,6}, T. Slowinski³, C. Neuber², B. Kleuser^{2†} and B. Hocher^{1,7,8*†}

Abstract

Background: Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes. It is known that GDM is associated with an altered placental function and changes in placental gene regulation. More recent studies demonstrated an involvement of epigenetic mechanisms. So far, the focus regarding placental epigenetic changes in GDM was set on gene-specific DNA methylation analyses. Studies that robustly investigated placental global DNA methylation are lacking. However, several studies showed that tissue-specific alterations in global DNA methylation are independently associated with type 2 diabetes. Thus, the aim of this study was to characterize global placental DNA methylation by robustly measuring placental DNA 5-methylcytosine (5mC) content and to examine whether differences in placental global DNA methylation are associated with GDM.

Methods: Global DNA methylation was quantified by the current gold standard method, LC-MS/MS. In total, 1030 placental samples were analyzed in this single-center birth cohort study.

Results: Mothers with GDM displayed a significantly increased global placental DNA methylation (3.22 ± 0.63 vs. 3.00 ± 0.46 %; $p = 0.013$; \pm SD). Bivariate logistic regression showed a highly significant positive correlation between global placental DNA methylation and the presence of GDM ($p = 0.0009$). Quintile stratification according to placental DNA 5mC levels revealed that the frequency of GDM was evenly distributed in quintiles 1–4 (2.9–5.3 %), whereas the frequency in the fifth quintile was significantly higher (10.7 %; $p = 0.003$). Bivariate logistic models adjusted for maternal age, BMI, ethnicity, recurrent miscarriages, and familiar diabetes predisposition clearly demonstrated an independent association between global placental DNA hypermethylation and GDM. Furthermore, an ANCOVA model considering known predictors of DNA methylation substantiated an independent association between GDM and placental DNA methylation.

Conclusions: This is the first study that employed a robust quantitative assessment of placental global DNA methylation in over a thousand placental samples. The study provides large scale evidence that placental global DNA hypermethylation is associated with GDM, independent of established risk factors.

Keywords: Placenta, Gestational diabetes, Insulin resistance, LC-MS/MS, Global DNA methylation, Epigenetics, Hypermethylation

* Correspondence:

hocher@uni-potsdam.de; <http://www.uni-potsdam.de/eem>

C. Reichetzeder and S. E. Dwi Putra are equally contributing first authors.

B. Kleuser and B. Hocher are equally contributing last authors.

[†]Equal contributors

¹Department of Experimental Nutritional Medicine, Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee 114-116, Nuthetal, Potsdam 14558, Germany

⁷Institut für Laboratoriumsmedizin, Berlin, Germany

Full list of author information is available at the end of the article



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with a first recognition during pregnancy [1]. In population based studies, the prevalence of GDM varies from 1 to 14 % with higher occurrences in specific populations [1, 2]. Ethnic disparities are existing, with Asians having the highest rate of GDM, followed by Hispanics, African Americans, and Caucasians [1]. GDM is associated with a markedly increased risk of adverse pregnancy outcome for both mother and infant. Mothers suffering from GDM have a higher risk for preeclampsia and cesarean delivery [3–5]. GDM pregnancies are associated with an increased perinatal morbidity and mortality, with an elevated risk for malformations, substantially higher rates of premature birth and neonatal hypoglycemia [3–5]. Newborns of pregnancies complicated by GDM show an increased risk to display altered growth patterns with increased neonatal body fat and a higher birth weight and ponderal index [3–5]. Evidence is accumulating that the intrauterine exposure to GDM also might contribute to long-lasting effects on the offspring by metabolic programming, leading to a higher disease susceptibility later in life [1]. Risk factors for GDM include age, a pre-pregnancy body mass index (BMI) >25.0 kg/m², ethnic background, a history of GDM in previous pregnancies, glucosuria, a strong first-degree family history of type 2 diabetes or GDM, and a history of unexplained stillbirth or recurrent miscarriages [6, 7]. The placenta is the primary means of communication between mother and fetus and a target for maternal and/or fetal metabolic disturbances associated with GDM. Placentas of diabetic pregnancies show an increased placental to fetal ratio and are characterized by pathohistological findings [8]. The increased risk for adverse pregnancy outcome in GDM may be associated with these placental structural and functional changes. The molecular pathways behind this are incompletely understood so far. It is known that GDM is associated with altered placental gene regulation, and there is data indicating an involvement of epigenetic mechanisms [9–13]. So far, the focus regarding placental epigenetic changes in GDM was predominantly set on gene specific DNA methylation [10–13]. There are several studies that applied genome wide approaches, using the Illumina Infinium 450K BeadChips assay that measures CpG island methylation in about 99 % of all RefSeq genes [11–13]. However, such arrays only cover about 1.5 % of overall genomic CpGs, are biased towards the measurement of promoter methylation, and neglect other regions and functions of DNA methylation, thus cannot be regarded as a method to measure global DNA methylation [14, 15]. Furthermore, only about 1.5 % of the total genome sequence is comprised of protein encoding genes, while the remaining

majority encompasses introns, repetitive elements, and other non-coding sequences [16]. Recent research has demonstrated important functions of DNA methylation in such non-coding genomic regions [14, 15, 17–19]. Although various sequencing methods are available for a detailed, site-specific analysis of global DNA methylation, these methods are very costly and time consuming, rendering them impracticable for DNA methylation analysis of large sample sizes [20]. Previous studies have demonstrated that the placenta is characterized by global DNA hypomethylation, usually a hallmark of various cancers. Next to global DNA hypomethylation, the placenta shares many features found in metastatic tumors, including rapid proliferation, invasiveness, and angiogenesis [21]. It was hypothesized that global DNA hypomethylation might support the unique functions of this organ [21–23]. Accordingly, alterations in the degree of global DNA methylation might be associated with altered placental function and disease. Until now, there are no large scale clinical studies that characterized global placental DNA methylation, assessed by an absolute quantification of the genomic 5-methylcytosine (5mC) content, in healthy and GDM afflicted pregnancies [24]. Thus, the aim of this study was to analyze global DNA methylation in over a thousand placental samples by the current gold standard method, LC-MS/MS, to truly assess the degree of global placental DNA methylation in uncomplicated pregnancies and to investigate whether GDM is associated with alterations in global placental DNA methylation.

Results

Table 1 displays detailed descriptive statistics of the 1030 mothers and their newborns and descriptive statistics of the study population grouped according to the presence or absence of GDM. Considering that patient recruitment was performed at a university clinic, the cohort did not display any uncommon features. The mean age of the mothers was 30.0 ± 5.9 years, and the mean BMI before pregnancy was 23.1 ± 4.5 kg/m²; 93.5 % of all mothers were of Caucasian, 0.9 % of African, 3.7 % of Asian, and 1.9 % of other ethnic background. Of all mothers, 5.4 % developed diabetes during pregnancy. The overall mean degree of placental DNA methylation was 3.01 ± 0.48 %. Data were normally distributed. Also shown in Table 1 are detailed descriptive statistics of the study population grouped according to the presence of GDM ($n = 56$) or no GDM ($n = 974$). Mothers with GDM had a significantly higher degree of placental global DNA methylation (3.22 ± 0.63 vs. 3.00 ± 0.46 %; $p = 0.013$; \pm SD, Fig. 1), were older (31.9 ± 5.1 vs. 29.8 ± 5.9 years; $p = 0.011$; \pm SD), and had higher HbA1c concentrations (58 ± 3.3 vs. 42 ± 6.6 mmol/mol; $p < 0.0001$; \pm SD) and a significantly elevated BMI at

Table 1 Descriptive data of all mother/child pairs and grouped according to GDM

Maternal characteristics	All mothers (<i>n</i> = 1030)	Presence of GDM		<i>p</i> value ^a
		No GDM (<i>n</i> = 974)	GDM (<i>n</i> = 56)	
Maternal age, years	30.0 ± 5.9	29.8 ± 5.9	31.9 ± 5.1	0.011
Ethnicity (Caucasian, non-Caucasian), %	93.5/6.5	93.5/6.5	92.9/7.1	0.842
Maternal height, cm	166.9 ± 7.0	167.0 ± 6.9	166.4 ± 8.4	0.637
Body mass index before pregnancy, kg/m ²	23.1 ± 4.5	23.0 ± 4.4	24.8 ± 5.8	0.027
Body mass index 3rd trimester, kg/m ²	27.6 ± 4.5	27.5 ± 4.4	29.6 ± 5.3	0.005
Hypertension before/during pregnancy, %	2.3/3.8	2.3/3.6	1.8/7.1	0.809/0.331
Diabetes mellitus before/during pregnancy, %	0.0/5.4	0.0/0.0	0.0/100.0	–
Diabetes in family, %	38.1	37.7	44.6	0.300
Mean systolic blood pressure 3rd trimester, mmHg	116.2 ± 11.1	116.3 ± 11.1	114.1 ± 10.9	0.159
Mean diastolic blood pressure 3rd trimester, mmHg	70.3 ± 7.5	70.4 ± 7.5	69.4 ± 8.4	0.345
Smoking before/during pregnancy, %	35.3/13.6	35.5/13.7	32.1/12.5	0.613/0.801
Placental DNA methylation, %	3.01 ± 0.48	3.00 ± 0.46	3.22 ± 0.63	0.013
Parity number ≤1/≥2, %	75.7/24.3	75.9/24.1	72.2/27.8	0.545
s/p 2 or more miscarriages, %	6.5	6.4	8.9	0.449
Twin gestations, %	2.1	2.1	3.6	0.445
Gestational age at delivery, weeks	38.7 ± 2.1	38.7 ± 2.1	38.4 ± 1.8	0.056
Preterm birth (<37 weeks), %	10.3	10.4	8.9	0.728
Birth weight, g	3339.6 ± 634.8	3329.8 ± 627.1	3509.6 ± 742.5	0.039
AGA/SGA/LGA, %	77.7/13.0/9.4	78.6/12.9/8.6	62.5/14.3/23.2	0.001
Birth length, cm	50.6 ± 3.2	50.6 ± 3.1	50.3 ± 5.0	0.626
Child head circumference, cm	34.7 ± 1.7	34.7 ± 1.7	34.6 ± 1.8	0.719
Ponderal index, kg/m ³	25.5 ± 2.5	25.4 ± 2.5	26.5 ± 3.0	0.002
Mode of delivery (spontaneous, OVD, c-section; %)	67.1/7.4/25.5	67.9/7.7/24.4	56.4/3.6/40.0	0.030
Child sex, male/female, %	51.7/48.3	51.6/48.4	53.6/46.4	0.780
Apgar score at 5 min	9.3 ± 1.0	9.3 ± 1.0	9.3 ± 0.9	0.996
Apgar score at 10 min	9.6 ± 0.8	9.6 ± 0.8	9.5 ± 0.7	0.137
Maternal HbA1c, %	6.1 ± 0.7	5.8 ± 3.3	4.2 ± 6.6	<0.0001

Data are given as mean ± SD or percentage

^aComparison between "GDM" and "no GDM"

the beginning and in the third trimester of pregnancy (24.8 ± 5.8 vs. 23.0 ± 4.4 kg/m²; *p* = 0.027; 29.6 ± 5.3 vs. 27.5 ± 4.4 kg/m²; *p* = 0.005). Newborns of GDM mothers had a significantly increased birth weight (3509.6 ± 742.5 vs. 3329.8 ± 627.1 g; *p* = 0.039), had an increased ponderal index (26.5 ± 3.0 vs. 25.4 ± 2.5; *p* = 0.002), and were more often delivered by c-section (40.0 vs 24.4 %; *p* = 0.030). Furthermore, the distribution of appropriate (AGA), small (SGA), and large (LGA) for gestational age newborns was significantly shifted towards a higher prevalence of LGA births in GDM mothers (62.5 % AGA/14.3 % SGA/23.2 % LGA vs. 78.6 % AGA/12.9 % SGA/8.6 % LGA; *p* = 0.001). LGA was also associated with significantly increased placental DNA methylation (3.19 ± 0.55 %) compared to SGA (3.01 ± 0.43 %; *p* < 0.01) and AGA (2.99 ± 0.47 %; *p* < 0.001).

Bivariate logistic regression showed a highly significant correlation between placental DNA methylation and presence of GDM in an unadjusted model (Exp(B): 2.373; 95 % CI 1.425–3.954; *p* = 0.0009). To further categorize this relationship, quintiles of placental DNA methylation were generated (five groups of *n* = 206) and analyzed in crosstabs for the frequency distribution of gestational diabetes. Figure 2 shows a cross tabulation of placental DNA methylation ranked in quintiles and the occurrence of GDM. The frequency of GDM was evenly distributed in quintiles 1–4 with frequencies ranging between 2.9 and 5.3 %, only in the fifth quintile a significantly higher GDM frequency of 10.7 % was found (Pearson chi square 16.127; *p* = 0.003; Fig. 2). This observation was even more significant after re-stratification into two groups, the first consisting of placental DNA methylation quintiles 1–4 (*n* = 824) and the




Fig. 1 Box and whiskers plot displaying the mean global placental DNA 5mC content, according to the presence or absence of GDM. Mothers with GDM had significantly higher mean levels (3.00 %; min 2.02 %; max 4.84 %) of 5mC than mothers without GDM (3.22 %; min 2.03 % max 4.73 %); #: p=0.013


second of methylation quintile 5 ($n = 206$) (Pearson chi-square 13.766; $p = 0.0002$; Table 2).

Table 2 shows detailed descriptive statistics of the study population according to the abovementioned stratification into lower degrees of placental DNA methylation (quintiles 1–4; $n = 824$) versus high placental DNA methylation (quintile 5; $n = 206$). There were significant differences regarding the ethnic composition of the highest methylation group vs. methylation quintiles 1–4, with more non-Caucasians in the highest methylation group (9.7 vs. 5.7 %; $p = 0.037$). There was a significantly higher frequency of

GDM in the highest methylation group (10.7 vs. 4.1 %; $p = 0.0002$). Moreover, a significant increase of LGA births was observed in the highest methylation group (73.0 % AGA, 12.7 % SGA, 14.2 % LGA vs. 78.8 % AGA, 13.0 % SGA, 8.2 % LGA; $p = 0.028$). Additionally, the Apgar score 10 min postnatally was significantly reduced in the highest methylation group (9.5 ± 0.8 vs. 9.6 ± 0.7 ; $p = 0.011$).

Adjusted bivariate logistic regression models

To demonstrate that a high degree of placental DNA methylation is independently associated with GDM,



Chi-Square: 16.127; $p=0.003$;

		DNA Methylation quintiles					
		1	2	3	4	5	
GDM	No	Count	195	200	200	195	184
		% within quintile	94.7%	97.1%	97.1%	94.7%	89.3%
GDM	Yes	Count	11	6	6	11	22
		% within quintile	5.3%	2.9%	2.9%	5.3%	10.7%
Total		Count	206	206	206	206	206

Fig. 2 Crosstabulation of GDM and placental DNA methylation ranked in quintiles. Ranges of placental DNA 5mC are depicted on top each respective quintile as box and whisker plots (mean; min; max)

Table 2 Descriptive data of the mother/child pairs grouped according to the degree of placental DNA methylation

Maternal characteristics	Degree of placental DNA methylation		<i>p</i> value ^a
	Quintiles 1–4 (<i>n</i> = 824)	Quintile 5 (<i>n</i> = 206)	
Maternal age, years	29.9 ± 6.0	30.3 ± 5.5	0.407
Ethnicity (Caucasian, non-Caucasian), %	94.3/5.7	90.3/9.7	0.037
Maternal height, cm	167.0 ± 6.9	166.5 ± 7.3	0.365
Body mass index before pregnancy, kg/m ²	23.2 ± 4.5	22.8 ± 4.4	0.094
Body mass index 3rd trimester, kg/m ²	27.6 ± 4.5	27.4 ± 4.3	0.801
Hypertension before/during pregnancy, %	2.0/3.5	3.4/4.9	0.200/0.443
Diabetes mellitus during pregnancy, %	4.1	10.7	0.0002
Diabetes in family, %	38.1	38.2	0.964
Mean systolic blood pressure 3rd trimester, mmHg	116.4 ± 11.0	115.3 ± 11.5	0.202
Mean diastolic blood pressure 3rd trimester, mmHg	70.4 ± 7.5	70.0 ± 7.5	0.491
Smoking before/during pregnancy, %	35.4/13.3	34.6/14.7	0.828/0.635
Placental DNA methylation, %	2.84 ± 0.32	3.71 ± 0.34	<0.0001
Parity number <2/≥2, %	76.1/23.9	73.8/26.2	0.481
s/p 2 or more miscarriages, %	6.3	7.3	0.613
twin gestations, %	1.8	3.4	0.161
Gestational age at delivery, weeks	38.7 ± 2.1	38.8 ± 1.8	0.989
Preterm birth (<37 weeks), %	10.3	10.3	0.983
Birth weight, g	3334.8 ± 628.3	3358.5 ± 661.4	0.634
AGA/SGA/LGA, %	78.8/13.0/8.2	73.0/12.7/14.2	0.028
Birth length, cm	50.6 ± 3.1	50.5 ± 3.6	0.951
Child head circumference, cm	34.7 ± 1.7	34.6 ± 1.7	0.436
Ponderal index, kg/m ³	25.5 ± 2.5	25.5 ± 2.7	0.943
Mode of delivery (spontaneous, OVD, c-section; %)	66.2/8.1/25.8	70.1/5.2/24.7	0.387
Child sex, male/female, %	52.3/47.7	49.8/50.2	0.522
Apgar score at 5 min	9.3 ± 1.0	9.2 ± 1.1	0.084
Apgar score at 10 min	9.6 ± 0.7	9.5 ± 0.8	0.011
Maternal HbA1c, m	43 ± 7.7	45 ± 8.7	0.257

Data are given as mean ± SD or percentage

^aComparison between "Quintiles 1–4" and "Quintile 5"

adjusted bivariate logistic regression models were calculated. To account for confounding, the models were adjusted for available parameters known to be risk factors for GDM [6]. Risk factors included in the models were maternal age, BMI at the beginning of pregnancy, a history of recurrent (≥2) miscarriages (yes; no), ethnic background (Caucasian; non-Caucasian), and family history of type 2 diabetes (yes; no). Model A used these confounders together with placental DNA methylation as a continuous variable. In this model, placental DNA methylation was significantly associated with the presence of GDM ((exp)B = 2.408; 95 % CI 1.427–4.063; *p* = 0.001; Table 3). In model B, placental DNA methylation stratified into the before mentioned two groups of high placental DNA methylation

(quintile 5; *n* = 206) and lower degrees of placental DNA methylation (quintiles 1–4; *n* = 824) was used. Grouped placental DNA methylation was associated with the presence of GDM even more significantly ((exp)B = 2.999; 95 % CI 1.691–5.316; *p* = 0.0002; Table 3).

Adjusted ANCOVA model

To demonstrate that GDM is independently associated with global placental DNA methylation, an ANCOVA model was calculated and adjusted for predictors of DNA methylation evinced in previous methylation studies [25, 26]. These factors included smoking status before pregnancy (yes/no), ethnic background (Caucasian; non-Caucasian), sex of the child (male/female), and age

Table 3 Model A: logistic regression investigating an association between placental DNA methylation and GDM; model B: logistic regression investigating an association between placental DNA methylation grouped into the fifth quintile ($n = 206$) versus quintiles 1–4 ($n = 824$) and GDM

Model A	B	S.E.	Sig.	Exp(B)	95 % CI for Exp(B)	
Constant	-8.647 ± 1.589; $p < 0.0001$				Lower	Upper
Maternal age, years	0.061	0.026	0.017	1.063	1.011	1.118
BMI beginning of pregnancy, kg/m ²	0.067	0.025	0.008	1.069	1.018	1.124
S/p 2 or more miscarriages, %	-0.128	0.502	0.798	0.880	0.329	2.351
Ethnicity (Caucasian, other)	-0.111	0.558	0.842	0.895	0.300	2.669
Diabetes in family (yes/no)	-0.318	0.289	0.271	0.728	0.413	1.281
Placental DNA methylation, %	0.879	0.267	0.001	2.408	1.427	4.063
Model B	B	S.E.	Sig.	Exp(B)	95 % CI for Exp(B)	
Constant	-5.240 ± 1.275; $p < 0.0001$				Lower	Upper
Maternal age, years	0.061	0.026	0.017	1.063	1.011	1.118
BMI beginning of pregnancy, kg/m ²	0.073	0.025	0.004	1.076	1.024	1.13
S/p 2 or more miscarriages, (%)	-0.143	0.501	0.775	0.867	0.325	2.314
Ethnicity (Caucasian, other)	-0.139	0.554	0.802	0.87	0.294	2.579
Diabetes in family (yes/no)	-0.314	0.289	0.277	0.731	0.415	1.286
Placental DNA methylation (grouped)	1.098	0.292	0.0002	2.999	1.691	5.316

of the mother. GDM was the strongest predictor of global placental DNA methylation ($B = 0.215$; 95 % CI 0.087–0.342; $p = 0.001$; Table 4) in this model. Additionally, the maternal smoking status before pregnancy was also significantly associated with global placental DNA methylation ($B = -0.064$; 95 % CI -0.126–0.002; $p = 0.044$; Table 4). Ethnicity of the mother, sex of the child, and maternal age showed no association with global placental DNA methylation (Table 4).

Discussion

The current study showed in a normally constituted cohort of delivering woman that there is a significant positive correlation between the degree of placental DNA methylation and GDM, i.e., higher levels of placental 5mC are associated with a higher frequency of GDM. Analyzing the mean levels of placental 5mC according to the presence or absence of GDM showed significantly

higher mean values in GDM mothers. For a better understanding of the relationship between methylation and the risk for GDM, mothers were ranked in quintiles according to the degree of placental DNA methylation. This revealed a significantly elevated frequency of GDM in the fifth quintile. Calculating different bivariate logistic regression models with placental DNA methylation as continuous and categorical variable, adjusted for known risk factors of GDM, underlined an independent association between placental DNA hypermethylation and GDM. An ANCOVA model adjusted for known factors influencing DNA methylation further substantiated the independent association between global placental DNA hypermethylation and GDM.

One limitation of the current study is that no large data sets of continuous variables describing GDM were available, only categorical variables displaying the final diagnosis. Yet, measured term HbA1c concentrations in

Table 4 ANCOVA analysis of the interaction between factors known to influence global DNA methylation, GDM, and global placental DNA methylation

Dependent variable: DNA methylation; $r^2 = 0.016$	B	S.E.	Power	Sig.	95 % CI for B	
					Lower	Upper
Intercept	3.06	0.091	1.000	<0.0001	2.881	3.239
GDM (yes/no)	0.215	0.065	0.911	0.001	0.087	0.342
Smoking before pregnancy (yes/no)	-0.064	0.032	0.521	0.044	-0.126	-0.002
Ethnicity (Caucasian, other)	0.112	0.061	0.457	0.064	-0.007	0.231
Sex of the child (male/female)	-0.032	0.03	0.191	0.279	-0.09	0.026
Maternal age, years	0.000	0.003	0.05	0.955	-0.005	0.005

a subset of mothers ($n = 94$), which were significantly elevated in GDM mothers, reinforced a correct diagnosis of GDM. Another limitation of this study is the usage of placental tissue without focusing on a specific placental cell type. Given the large sample size (>1000 placenta samples), purification of specific placental cell types was not feasible. However, it was shown by MethylC-seq analysis that global methylation in whole rhesus placental tissue was almost identical compared to isolated rhesus trophoblast cell methylation with a correlation of 0.89 [21]. Next to the mentioned limitations, this study exhibits several strengths. To the best of our knowledge, it is by now the largest study of its kind analyzing placental DNA methylation and clinical readouts in 1030 mothers. Moreover, it is the first study that uses a robust quantitative assessment of placental global DNA methylation, employing the current gold standard LC-MS/MS [24]. All other studies investigating placental DNA methylation so far were either small, employed only semiquantitative methods of measuring global DNA methylation, or were focused on specific DNA methylation [9–12, 27]. Given the absence of studies with a comparable study design in regard to sample size, analyzed tissue, and the method of global DNA methylation assessment, interpretation of the results of the current study in context with available literature warrants caution.

Average levels of global placental DNA methylation were 3.00 ± 0.46 % in uncomplicated pregnancies. This is in agreement with another study analyzing global placental DNA methylation using HPLC, also demonstrating global DNA hypomethylation in comparison to average global DNA methylation levels observed in somatic tissues [28].

The current study demonstrated a positive association between GDM and global placental DNA methylation. Notwithstanding, a previous preliminary study by *Nomura* et al. showed a negative association between global placental DNA methylation and GDM [9]. However, as only 50 placenta samples were analyzed for global DNA methylation, the observed difference in results is most likely attributable to the ~20-fold smaller study size. Additionally, the semiquantitative luminometric methylation assay was used for the measurement of global DNA methylation, which was shown to be outperformed by other approaches of global DNA methylation assessment, especially regarding inter-assay comparability [9, 24, 29].

Two studies, investigating placental DNA methylation in GDM using the Illumina Infinium 450K BeadChips array, found a predominance of hypermethylation at methylation variable positions in GDM exposed placental samples [11, 12]. However, such arrays only cover about ~1.5 % of all genomic CpGs [14]. Therefore, the results of these studies have limited value in discussing the current observations [14].

Several clinical studies, investigating global DNA methylation in type 2 diabetes showed higher levels of global DNA methylation in different types of peripheral blood cells of diabetic patients [30–36]. Global methylation in these studies was assessed by LC/MS-MS [30, 33–35] or LC/MS-MS validated methods [31] or by measuring surrogate parameters of global DNA methylation like LINE-1 or Alu elements [32, 36]. The analysis of global DNA methylation in leukocytes is a well used method in epidemiologic studies to display associations between global DNA methylation and disease [35, 37, 38]. However, whether changes in global leukocyte DNA methylation associated with an insult (e.g., diabetes) also reflect aligned methylation changes in other tissues remains elusive. Nevertheless, a general hypothesis raised by *Zhao* et al., speculating that a putative link between global DNA hypermethylation and diabetes could be genomic instability, might also apply for findings of the current study [32]. The hypothesis is supported by findings of other studies [39–41], and there is ample amount of evidence that genomic instability is not only a hallmark of cancer but also associated with insulin resistance [42–44]. An underlying factor bearing implications for both genomic instability and DNA hypermethylation might be oxidative stress. Literature suggests that oxidative stress is involved in the development of metabolic diseases [45]. Diabetes itself is associated with increased oxidative stress, and it is well described that oxidative stress can induce DNA damage, another important factor in the development of diabetes [43, 45–47]. It was also shown that reactive oxygen species regulate the activity of DNA methyltransferases and catalyze the methylation of DNA [48, 49]. Moreover, it was demonstrated in animal models that an upregulation of the activity or the expression of DNA methyltransferases is observed in different types of diabetes [48, 50, 51]. Data from these recent animal experiments support a positive association between a diabetic metabolic state and global DNA methylation and additionally delineated putative mechanisms, connecting diabetes, oxidative stress, and global DNA hypermethylation [50, 51]. *Zhong* et al. have shown in a streptozotocin animal model of gestational diabetes that maternal diabetes induces an increased expression of DNA methyltransferases, increased DNA methyltransferase activity, and increased global DNA methylation (measured by MethylFlash Methylated DNA Quantification Kit which analyzes global 5mC content) in E8.75 embryos. Notably, treatment with the polyphenol epigallocatechin gallate, which was shown to exert anti-oxidative effects and to inhibit DNA methyltransferase activity, abrogated these changes [51–53].

Conclusions

In summary, this study provides the first large scale evidence that placental global DNA hypermethylation is

associated with GDM independent of established risk factors. The results of the study are in agreement with other studies; however, many of the comparable studies investigated DNA methylation in type 2 diabetes, in other organs than the placenta or by different methods of global DNA methylation assessment. Nevertheless, there is substantial evidence in literature from both clinical and preclinical experimental studies supporting an association between a diabetic metabolic state and global DNA hypermethylation. The results of the current study have to be confirmed using comparable methods, to substantiate our understanding of global DNA methylation involvement in disease. In general, a harmonization of applied methodology for the measurement of global DNA methylation is warranted. Differently designed studies will be needed to demonstrate a causal relationship between global DNA hypermethylation and GDM and to elucidate the still very elusive question whether aberrant global DNA methylation is involved in the pathogenesis of GDM or a consequence of this disease.

Methods

Ethics, consent, and permissions

The study was approved by the ethics committee of the university hospital Charité, Berlin, Germany. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Written, informed consent was obtained from all partaking mothers prior to data collection.

Clinical study

This observational all-comers study included 1063 mothers delivering at the obstetrics department of Campus Charité Mitte, Berlin, Germany. Structured interviews were performed with the partaking mothers. Eleven mothers with overt diabetes before pregnancy, nine cases of preeclampsia, and 13 cases with incomplete data of the most important variables and confounders were excluded from the statistical analyses. Given a potential overlap regarding pathophysiological processes leading to preeclampsia and GDM and the low sample number of preeclamptic placentas in the current study, it stood to reason to exclude mother with preeclampsia [9, 54]. In total, 1030 mothers were included into the statistical analyses. The majority of mothers ($n = 963$; 93.5 %) were of Caucasian ethnicity, while 67 mothers (6.5 %) had other ethnic backgrounds. Data from the “Mutterpass” documenting the results of follow ups during pregnancy were also collected. The following data were available for the dataset: age, ethnicity, body height, body mass index (BMI) at the beginning of pregnancy, body mass index (BMI) at the third trimester of pregnancy, parity, diabetes mellitus before or during pregnancy, family history of diabetes, incidence of hypertension before and during

pregnancy, smoking before and during pregnancy, systolic and diastolic blood pressure measurements recorded during pregnancy, and in a small subset ($n = 94$) of mothers, maternal HbA1c levels at term. GDM was screened and assessed in all mothers according to the practice guideline of the German Diabetes Association (DGG) and the German Association for Gynaecology and Obstetrics (DGGG) [55]. Biometric data of the newborn were collected during the routine postnatal examination. Gestational age at delivery was based on the last menstrual period, anamnesticly assessed during the first pregnancy examination. The following data of the newborn were added to the database: birth weight, birth length, head circumference, child sex, Apgar score 5 min postnatally and Apgar score 10 min postnatally. A standardized placenta sample—1 complete cotyledon (cross section of all layers) from similar locations—was collected and immediately frozen and stored at $-20\text{ }^{\circ}\text{C}$. For the extraction of DNA a sample of chorionic villi was obtained from the whole cotyledon.

Data were analyzed using SPSS version 20.0 (SPSS, Inc, Chicago, IL, USA). Depending on normal distribution, unpaired t test or Mann-Whitney U test was used when comparing mean values of two groups. For the comparison of categorical variable distribution, chi-square test was used. Bivariate logistic regression was used to analyze the relationship of continuous and categorical data with a categorical outcome, to confirm relevant confounding variables that had an independent influence, and to adjust for these in different statistical models. To calculate associations between a continuous dependent variable and both categorical and continuous independent variables, ANCOVA models were used. Bar graphs were calculated and compiled with Graphpad Prism 5 (GraphPad Software Inc., La Jolla, California, USA). Probability values <0.05 were considered significant. The authors had full access to the data and take full responsibility for its integrity.

Analysis of DNA methylation

DNA was extracted using a QIAamp DNA Mini Kit from Qiagen (Hilden, Germany) together with a RNase A digestion according to the manufacturer's protocol. The concentration and quality of the RNA-free DNA solution were determined by a NanoDrop ND-1000 spectrophotometer. DNA hydrolysis was carried out using DNA Degradase Plus from Zymo Research (Freiburg, Germany). Briefly, 1 μg of genomic DNA was mixed with 2.5 μL 10 \times DNA Degradase Reaction Buffer, and 1 μL DNA Degradase Plus and filled up with water to a volume of 25 μL . DNA hydrolysis was stopped after 4 h at 37 $^{\circ}\text{C}$ by adding 75 μL of 0.1 % formic acid. Agarose gel electrophoresis using 200 ng of the digested DNA was employed in order to control the completeness of digestion. Seventy microliters of the hydrolysed DNA

samples were further diluted with 280 μ L 0.1 % formic acid to yield a final concentration of 2 ng digested DNA/ μ L. DNA methylation was assessed by liquid chromatography-electrospray ionization/multi-stage mass spectrometry (LC-ESI/MS/MS) technique as described previously [56]. LC-ESI/MS/MS was performed with an Agilent 1200 series HPLC system connected to an Agilent 6530 Accurate-Mass Q-TOF instrument with Jet Stream-Interface (Waldbronn, Germany). For chromatographic separation a Waters (Milford, MA) X-BridgeTM C18 4.6 mm \times 150 mm (3.5- μ m particle size) protected by a Waters X-BridgeTM C18 4.6 mm \times 20 mm guard column (5- μ m particle size) was used. 0.1 % formic acid in water (solvent A) and 0.1 % formic acid in methanol (solvent B) were chosen as mobile phases. The linear gradient elution was 4–20 % of solvent B in 10 min at a constant flow rate of 0.5 mL/min. Fifty microliters of the diluted DNA hydrolysis samples, typically containing 100-ng digested DNA, were injected. The optimized ESI-MS/MS parameters in the positive ion mode were as follows: gas temperature, 250 °C; drying gas flow, 8 L/min; nebulizer pressure, 60 psig; sheath gas temperature, 300 °C; capillary voltage 4000 V; and collision energy 7 V for dC, 13 V for 5mdC, and 10 V for dG. Quantification was accomplished in selected reaction monitoring (SRM) mode by monitoring a transition pair of m/z 228.0979/112.0505 for dC, m/z 242.1135/126.0662 for 5mdC, and m/z 268.1040/152.0780 for dG, which was used as an internal standard for the measurement. The scan time was 333 ms for each pair. The deoxyribonucleosides 2'-deoxyguanosine (dG) monohydrate, 5-methyl-2'-deoxycytidine (5mdC) and 2'-deoxycytidine (dC) were purchased from ABCR (Karlsruhe, Germany). Herring sperm DNA was obtained from Sigma-Aldrich (Hamburg, Germany). Nuclease-free water used for DNA extraction was purchased from Roth (Karlsruhe, Germany). LC-MS-grade water, methanol, and formic acid were purchased from VWR international, Inc. (Dresden, Germany). The global level of DNA methylation was calculated as the percentage of DNA methylation as follows: DNA methylation % = 5-methyl-2'-deoxycytidine (5mdC)/[5-methyl-2'-deoxycytidine (5mdC) + 2'-deoxycytidine (dC)] \times 100 %.

Abbreviations

5mC, 5-methylcytosine; AGA, appropriate for gestational age; DGG German Diabetes Association; DGGG German Association for Gynaecology and Obstetrics; GDM, gestational diabetes mellitus; IADPSG, International Association of Diabetes in Pregnancy Study Group; LC-MS/MS, Liquid chromatography tandem mass spectrometry; LGA, large for gestational age; OVD, operative vaginal delivery; SGA, small for gestational age

Acknowledgements

Not applicable.

Funding

This study was partially funded by the Deutsche Forschungsgemeinschaft (DFG grant No. Ho1665/5-2 to Prof. Hocher).

Availability of data and materials

The dataset contains indirect identifiers. As there is some risk of identification, the dataset was not approved for publication in a freely accessible manner by the local ethics committee.

Authors' contributions

BH was responsible for the clinical study design. TP, TS, and BH conducted the clinical study, edited the manuscript, and contributed to the discussion. SEDP and CN performed the measurements of global DNA methylation and edited the manuscript. SEDP contributed to the discussion. CR wrote the manuscript and analyzed the data. BK coordinated the measurement of global DNA, edited the manuscript, and contributed to the discussion. BH is the guarantor of this work and had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study was approved by the institutional ethics committee of the university hospital Charité, Berlin, Germany. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Written, informed consent was obtained from all partaking mothers prior to data collection.

Author details

¹Department of Experimental Nutritional Medicine, Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee 114-116, Nuthetal, Potsdam 14558, Germany. ²Department of Toxicology, Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. ³Department of Nephrology, Campus Charité Mitte, University Hospital Charité, Berlin, Germany. ⁴Center for Cardiovascular Research (CCR), Campus Charité Mitte, University Hospital Charité, Berlin, Germany. ⁵Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia. ⁶Diaverum Deutschland, Potsdam, Germany. ⁷Institut für Laboratoriumsmedizin, Berlin, Germany. ⁸Department of Basic Medicine, Medical College of Hunan Normal University, Changsha, China.

Received: 26 April 2016 Accepted: 11 July 2016

Published online: 26 July 2016

References

- Lappas M, Hiden U, Desoye G, Froehlich J, Hauguel-de Mouzon S, Jaberbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. *Antioxid Redox Signal*. 2011;15:3061–100.
- Schneider S, Bock C, Wetzel M, Maul H, Loerbroks A. The prevalence of gestational diabetes in advanced economies. *J Perinat Med*. 2012;40:511–20.
- Coustan DR. Gestational diabetes mellitus. *Clin Chem*. 2013;59:1310–21.
- Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Aktary WM, et al. Screening and diagnosing gestational diabetes mellitus. Evidence Report/Technology Assessment no. 210. AHRQ Publication no. 12(13)-E021-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
- Gauster M, Desoye G, Tötsch M, Hiden U. The placenta and gestational diabetes mellitus. *Curr Diab Rep*. 2012;12:16–23.
- Reece EA, Leguizamón G, Wiznitzer A. Gestational diabetes: the need for a common ground. *Lancet*. 2009;373:1789–97.
- Schaefer-Graf P-DD med UM, Kautzky-Willer U-PD med A. Diabetes mellitus und Schwangerschaft. In: Schneider PD med H, Husslein U-PD med P-W, Schneider U-PD med KTM, editors. *Die Geburtshilfe*. Berlin: Springer; 2011. p. 435–56.
- Gabbay-Benziv R, Baschat AA. Gestational diabetes as one of the “great obstetrical syndromes”—the maternal, placental, and fetal dialog. *Best Pract Res Clin Obstet Gynaecol*. 2015;29:150–5.
- Nomura Y, Lambertini L, Rialdi A, Lee M, Mystal EY, Grabie M, et al. Global methylation in the placenta and umbilical cord blood from pregnancies with maternal gestational diabetes, preeclampsia, and obesity. *Reprod Sci*. 2014;21:131–7.

10. Bouchard L, Hivert M-F, Guay S-P, St-Pierre J, Perron P, Brisson D. Placental adiponectin gene DNA methylation levels are associated with mothers' blood glucose concentration. *Diabetes*. 2012;61:1272–80.
11. Ruchat S-M, Houde A-A, Voisin G, St-Pierre J, Perron P, Baillargeon J-P, et al. Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. *Epigenetics*. 2013;8:935–43.
12. Finer S, Mathews C, Lowe R, Smart M, Hillman S, Foo L, et al. Maternal gestational diabetes is associated with genome-wide DNA methylation variation in placenta and cord blood of exposed offspring. *Hum Mol Genet*. 2015;24(11):3021–9.
13. Binder AM, LaRocca J, Lesseur C, Marsit CJ, Michels KB. Epigenome-wide and transcriptome-wide analyses reveal gestational diabetes is associated with alterations in the human leukocyte antigen complex. *Clin Epigenetics*. 2015;7:79.
14. Busche S, Shao X, Caron M, Kwan T, Allum F, Cheung WA, et al. Population whole-genome bisulfite sequencing across two tissues highlights the environment as the principal source of human methylome variation. *Genome Biol*. 2015;16:290.
15. Patrushev LI, Kovalenko TF. Functions of noncoding sequences in mammalian genomes. *Biochemistry (Mosc)*. 2014;79:1442–69.
16. Gregory TR. Synergy between sequence and size in large-scale genomics. *Nat Rev Genet*. 2005;6:699–708.
17. Gelfman S, Cohen N, Yearim A, Ast G. DNA-methylation effect on cotranscriptional splicing is dependent on GC architecture of the exon-intron structure. *Genome Res*. 2013;23:789–99.
18. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation. *Trends Genet*. 2015;31:274–80.
19. Reddington JP, Pennings S, Meehan RR. Non-canonical functions of the DNA methylome in gene regulation. *Biochem J*. 2013;451:13–23.
20. Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. *Biology (Base)* [Internet]. 2016 [cited 2016 Jun 11];5. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810160/>
21. Schroeder DL, Jayashankar K, Douglas KC, Thirkill TL, York D, Dickinson PJ, et al. Early developmental and evolutionary origins of gene body DNA methylation patterns in mammalian placentas. *PLoS Genet*. 2015;11, e1005442.
22. Chatterjee A, Macaulay EC, Rodger EJ, Stockwell PA, Parry MF, Roberts HE, Slatter TL, Hung NA, Devenish CJ, Morison IM. Placental Hypomethylation Is More Pronounced in Genomic Loci Devoid of Retroelements. *G3 (Bethesda)*. 2016;6(7):1911–21. doi:10.1534/g3.116.030379.
23. Bianco-Miotto T, Mayne BT, Buckberry S, Breen J, Lopez CMR, Roberts CT. Recent progress towards understanding the role of DNA methylation in human placental development. *Reproduction*. 2016;152:R23–30.
24. Liu J, Hesson LB, Ward RL. Liquid Chromatography Tandem Mass Spectrometry for the Measurement of Global DNA Methylation and Hydroxymethylation. *Journal of Proteomics & Bioinformatics* [Internet]. Available from: http://www.omicsonline.org/proteomics-bioinformatics-abstract.php?abstract_id=15772
25. Tajuddin SM, Amaral AFS, Fernandez AF, Rodriguez-Rodero S, Rodriguez RM, Moore LE, et al. Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA. *Environ Health Perspect*. 2013;121:650–6.
26. Boeke CE, Baccarelli A, Kleinman KP, Burris HH, Litonjua AA, Rifas-Shiman SL, et al. Gestational intake of methyl donors and global LINE-1 DNA methylation in maternal and cord blood: prospective results from a folate-replete population. *Epigenetics*. 2012;7:253–60.
27. Lesseur C, Armstrong DA, Paquette AG, Li Z, Padbury JF, Marsit CJ. Maternal obesity and gestational diabetes are associated with placental leptin DNA methylation. *Am J Obstet Gynecol*. 2014;211(6):654.e1–9.
28. Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. *Ann Hum Genet*. 2004;68:196–204.
29. Lisanti S, Omar WAW, Tomaszewski B, De Prins S, Jacobs G, Koppen G, et al. Comparison of methods for quantification of global DNA methylation in human cells and tissues. *PLoS One*. 2013;8.
30. Maghbooli Z, Larjani B, Emamgholipour S, Amini M, Keshtkar A, Pasalar P. Aberrant DNA methylation patterns in diabetic nephropathy. *J Diabetes Metab Disord*. 2014;13:69.
31. Simar D, Versteyhe S, Donkin I, Liu J, Hesson L, Nylander V, et al. DNA methylation is altered in B and NK lymphocytes in obese and type 2 diabetic human. *Metab Clin Exp*. 2014;63:1188–97.
32. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. *Diabetes*. 2012;61:542–6.
33. Maghbooli Z, Hossein-Nezhad A, Larjani B, Amini M, Keshtkar A. Global DNA methylation as a possible biomarker for diabetic retinopathy. *Diabetes Metab Res Rev*. 2014;31(2):183–9.
34. Maghbooli Z, Hossein-Nezhad A, Larjani B, Pasalar P, Keshtkar AA. Association between alterations in global DNA methylation and predisposing factors in diabetes: a high pressure liquid chromatography based study. *Minerva Med*. 2015;106:221–31.
35. Maghbooli Z, Hossein-Nezhad A, Larjani B, Amini M, Keshtkar A. Global DNA methylation as a possible biomarker for diabetic retinopathy. *Diabetes Metab Res Rev*. 2015;31:183–9.
36. Pearce MS, McConnell JC, Potter C, Barrett LM, Parker L, Mathers JC, et al. Global LINE-1 DNA methylation is associated with blood glycaemic and lipid profiles. *Int J Epidemiol*. 2012;41:210–7.
37. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. *Epigenetics*. 2011;6:828–37.
38. Kim YO, Li C, Sun BK, Kim JS, Lim SW, Choi BS, et al. Preconditioning with 1,25-dihydroxyvitamin D3 protects against subsequent ischemia-reperfusion injury in the rat kidney. *Nephron Exp Nephrol*. 2005;100:e85–94.
39. Walters RJ, Williamson EJ, English DR, Young JP, Rosty C, Clendenning M, et al. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer. *Epigenetics*. 2013;8:748–55.
40. Neale RE, Clark PJ, Fawcett J, Fritschi L, Nagler BN, Risch HA, et al. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. *Cancer Epidemiol*. 2014;38:576–82.
41. Liao LM, Brennan P, van Bemmelen DM, Zaridze D, Matveev V, Janout V, et al. LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. *PLoS One*. 2011;6.
42. Moran LJ, Noakes M, Clifton PM, Norman RJ, Fenech MF. Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. *Mutat Res*. 2008;639:55–63.
43. Attia SM, Helal GK, Alhaider AA. Assessment of genomic instability in normal and diabetic rats treated with metformin. *Chem Biol Interact*. 2009;180:296–304.
44. Binici DN, Karaman A, Coşkun M, Oğlu AU, Uçar F. Genomic damage in patients with type-2 diabetes mellitus. *Genet Couns*. 2013;24:149–56.
45. Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. *Life Sci*. 2016;148:183–93.
46. Milic M, Frustaci A, Del Bufalo A, Sánchez-Alarcón J, Valencia-Quintana R, Russo P, et al. DNA damage in non-communicable diseases: a clinical and epidemiological perspective. *Mutat Res*. 2015;776:118–27.
47. Dong D, Yu J, Wu Y, Fu N, Villela NA, Yang P. Maternal diabetes triggers DNA damage and DNA damage response in neurulation stage embryos through oxidative stress. *Biochem Biophys Res Commun*. 2015;467:407–12.
48. Wei D, Loeken MR. Increased DNA methyltransferase 3b (Dnmt3b)-mediated CpG island methylation stimulated by oxidative stress inhibits expression of a gene required for neural tube and neural crest development in diabetic pregnancy. *Diabetes*. 2014;63:3512–22.
49. Hai Z, Zuo W. Aberrant DNA methylation in the pathogenesis of atherosclerosis. *Clin Chim Acta*. 2016;456:69–74.
50. Williams KT, Schalinske KL. Tissue-specific alterations of methyl group metabolism with DNA hypermethylation in the Zucker (type 2) diabetic fatty rat. *Diabetes Metab Res Rev*. 2012;28:123–31.
51. Zhong J, Xu C, Reece EA, Yang P. The green tea polyphenol EGCG alleviates maternal diabetes-induced neural tube defects by inhibiting DNA hypermethylation. *Am J Obstet Gynecol*. 2016. doi:10.1016/j.ajog.2016.03.009.
52. Fang MZ, Wang Y, Ai N, Hou S, Sun Y, Lu H, et al. Tea polyphenol (–)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res*. 2003;63:7563–70.
53. Legeay S, Rodier M, Fillon L, Faure S, Clere N. Epigallocatechin gallate: a review of its beneficial properties to prevent metabolic syndrome. *Nutrients*. 2015;7:5443–68.
54. Liu L, Zhang X, Rong C, Rui C, Ji H, Qian Y, et al. Distinct DNA methylomes of human placentas between pre-eclampsia and gestational diabetes mellitus. *Cell Physiol Biochem*. 2014;34:1877–89.
55. Kleinwechter H, Schäfer-Graf U, Bührer C, Hoesli I, Kainer F, Kautzky-Willer A, et al. Gestational diabetes mellitus (GDM) diagnosis, therapy and follow-up care. *Exp Clin Endocrinol Diabetes*. 2014;122:395–405.
56. Dwi Putra SE, Neuber C, Reichetzeder C, Hoher B, Kleuser B. Analysis of genomic DNA methylation levels in human placenta using liquid chromatography-electrospray ionization tandem mass spectrometry. *Cell Physiol Biochem*. 2014;33:945–52.

eased_global_placental_DNA_m ethylation_levels_are_associated .pdf

by Sulisty Slowinski

Submission date: 01-Feb-2021 05:41PM (UTC+0700)

Submission ID: 1498977019

File name: eased_global_placental_DNA_methylation_levels_are_associated.pdf (639.87K)

Word count: 8250

Character count: 42444

RESEARCH

Open Access



Increased global placental DNA methylation levels are associated with gestational diabetes

C. Reichetzeder^{2,4†}, S. E. Dwi Putra^{1,5†}, T. Pfab^{4,6}, T. Slowinski³, C. Neuber², B. Kleuser^{2†} and B. Hocher^{1,7,8*†}

Abstract

Background: Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes. It is known that GDM is associated with an altered placental function and changes in placental gene regulation. More recent studies demonstrated an involvement of epigenetic mechanisms. So far, the focus regarding placental epigenetic changes in GDM was set on gene-specific DNA methylation analyses. Studies that robustly investigated placental global DNA methylation are lacking. However, several studies showed that at tissue-specific alterations in global DNA methylation are independently associated with type 2 diabetes. Thus, the aim of this study was to characterize global placental DNA methylation by robustly measuring placental DNA 5-methylcytosine (5mC) content and to examine whether differences in placental global DNA methylation are associated with GDM.

Methods: Global DNA methylation was quantified by the current gold standard method, LC-MS/MS. In total, 1030 placental samples were analyzed in this single-center birth cohort study.

Results: Mothers with GDM displayed a significantly increased global placental DNA methylation (3.22 ± 0.63 vs. 3.00 ± 0.46 %; $p = 0.013$; \pm SD). Bivariate logistic regression showed a highly significant positive correlation between global placental DNA methylation and the presence of GDM ($p = 0.0009$). Quintile stratification according to placental DNA 5mC levels revealed that the frequency of GDM was evenly distributed in quintiles 1–4 (2.9–5.3 %), whereas the frequency in the fifth quintile was significantly higher (10.7 %; $p = 0.003$). Bivariate logistic models adjusted for maternal age, BMI, ethnicity, recurrent miscarriages, and familiar diabetes predisposition clearly demonstrated an independent association between global placental DNA hypermethylation and GDM. Furthermore, an ANCOVA model considering known predictors of DNA methylation substantiated an independent association between GDM and placental DNA methylation.

Conclusions: This is the first study that employed a robust quantitative assessment of placental global DNA methylation in over a thousand placental samples. The study provides large scale evidence that placental global DNA hypermethylation is associated with GDM, independent of established risk factors.

Keywords: Placenta, Gestational diabetes, Insulin resistance, LC-MS/MS, Global DNA methylation, Epigenetics, Hypermethylation

*Correspondence:

hocher@uni-potsdam.de; <http://www.uni-potsdam.de/eem>

C. Reichetzeder and S. E. Dwi Putra are equally contributing first authors.

B. Kleuser and B. Hocher are equally contributing last authors.

[†]Equal contributors

¹Department of Experimental Nutritional Medicine, Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee 114-116, Nuthetal, Potsdam 14558, Germany

²Institut für Laboratoriumsmedizin, Berlin, Germany

Full list of author information is available at the end of the article



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to this Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with a first recognition during pregnancy [1]. In population based studies, the prevalence of GDM varies from 1 to 14 % with higher occurrences in specific populations [1, 2]. Ethnic disparities are existing, with Asians having the highest rate of GDM, followed by Hispanics, African Americans, and Caucasians [1]. GDM is associated with a markedly increased risk of adverse pregnancy outcome for both mother and infant. Mothers suffering from GDM have a higher risk for preeclampsia and cesarean delivery [3–5]. GDM pregnancies are associated with an increased perinatal morbidity and mortality, with an elevated risk for malformations, substantially higher rates of premature birth and neonatal hypoglycemia [3–5]. Newborns of pregnancies complicated by GDM show an increased risk to display altered growth patterns with increased neonatal body fat and a higher birth weight and ponderal index [3–5]. Evidence is accumulating that the intrauterine exposure to GDM also might contribute to long-lasting effects on the offspring by metabolic programming, leading to a higher disease susceptibility later in life [75]. Risk factors for GDM include age, a pre-pregnancy body mass index (BMI) >25.0 kg/m², ethnic background [33], history of GDM in previous pregnancies, glucosuria, a strong first-degree family history of type 2 diabetes or GDM, and a history of unexplained stillbirth or recurrent miscarriages [6, 7]. The placenta is the primary means of communication between mother and fetus and a target for maternal and fetal metabolic disturbances associated with GDM. Placentas of diabetic pregnancies show an increased placental to fetal ratio and are characterized by pathohistological findings [8]. The increased risk for adverse pregnancy outcome in GDM may be associated with these placental structural and functional changes. The molecular ways behind this are incompletely understood so far. It is known that GDM is associated with altered placental gene regulation, and there is data indicating an involvement of epigenetic mechanisms [9–13]. So far, the focus regarding placental epigenetic changes in GDM was predominantly set on gene specific DNA methylation [10–13]. There are several studies that applied genome wide approaches, using the Illumina Infinium 450K BeadChips assay that measures CpG island methylation in about 99 % of all RefSeq genes [11–13]. However, such arrays only cover about 1.5 % of overall genomic CpGs, are biased towards the measurement of promoter methylation, and neglect other regions and functions of DNA methylation, thus cannot be regarded as a method to measure global DNA methylation [14, 15]. Furthermore, only about 1.5 % of the total genome sequence is comprised of protein encoding genes, while the remaining

majority encompasses introns, repetitive elements, and other non-coding sequences [16]. Recent research has demonstrated important functions of DNA methylation in such non-coding genomic regions [14, 15, 17–19]. Although various sequencing methods are available for a detailed, site-specific analysis of global DNA methylation, these methods are very costly and time consuming, rendering them impracticable for DNA methylation analysis of large sample sizes [20]. Previous studies have demonstrated that the placenta is characterized by global DNA hypomethylation, usually a hallmark of various cancers. Next to global DNA hypomethylation, the placenta shares many features found in metastatic tumors, including rapid proliferation, invasiveness, and angiogenesis [21]. It was hypothesized that global DNA hypomethylation might support the unique functions of this organ [21–23]. Accordingly, alterations in the degree of global DNA methylation might be associated with altered placental function and disease. Until now, there are no large scale clinical studies that characterized global placental DNA methylation, assessed by an absolute quantification of the genomic 5-methylcytosine (5mC) content, in healthy and GDM afflicted pregnancies [24]. Thus, the aim of this study was to analyze global DNA methylation in over a thousand placental samples by the current gold standard method, LC-MS/MS, to truly assess the degree of global placental DNA methylation in uncomplicated pregnancies and to investigate whether GDM is associated with alterations in global placental DNA methylation.

Results

Table 1 displays detailed descriptive statistics of the 1030 mothers and their newborns and descriptive statistics of the study population grouped according to the presence or absence of GDM. Considering that patient recruitment was performed at a university clinic, the cohort did not display any uncommon features. The mean age of the mothers was 30.0 ± 5.9 years, and the mean BMI before pregnancy was 23.1 ± 4.5 kg/m²; 93.5 % of all mothers were of Caucasian, 0.9 % of African, 3.7 % of Asian, and 1.9 % of other ethnic background. Of all mothers, 5.4 % developed diabetes during pregnancy. The overall mean degree of placental DNA methylation was 3.01 ± 0.48 %. Data were normally distributed. As shown in Table 1 are detailed descriptive statistics of the study population grouped according to the presence of GDM (*n* = 56) or no GDM (*n* = 974). Mothers with GDM had a significantly higher degree of placental global DNA methylation (3.22 ± 0.63 vs. 3.00 ± 0.46 %; *p* = 0.013; ±SD, Fig. 1), were older (31.9 ± 5.1 vs. 29.8 ± 5.9 years; *p* = 0.011; ±SD), and had higher HbA1c concentrations (58 ± 3.3 vs. 42 ± 6.6 mmol/mol; *p* < 0.0001; ±SD) and a significantly elevated BMI at


Table 1 Descriptive data of all mother/child pairs and grouped according to GDM

Maternal characteristics	All mothers (n = 1030)	Presence of GDM		p value ^a
		No GDM (n = 974)	GDM (n = 56)	
Maternal age, years	30.0 ± 5.9	29.8 ± 5.9	31.9 ± 5.1	0.011
Ethnicity (Caucasian, non-Caucasian), %	93.5/6.5	93.5/6.5	92.9/7.1	0.842
Maternal height, cm	166.9 ± 7.0	167.0 ± 6.9	166.4 ± 8.4	0.637
Body mass index before pregnancy, kg/m ²	23.1 ± 4.5	23.0 ± 4.4	24.8 ± 5.8	0.027
Body mass index 3rd trimester, kg/m ²	27.6 ± 4.5	27.5 ± 4.4	29.6 ± 5.3	0.005
Hypertension before/during pregnancy, %	2.3/3.8	2.3/3.6	1.8/7.1	0.809/0.331
Diabetes mellitus before/during pregnancy, %	0.0/5.4	0.0/0.0	0.0/100.0	–
Diabetes in family, %	38.1	37.7	44.6	0.300
Mean systolic blood pressure 3rd trimester, mmHg	116.2 ± 11.1	116.3 ± 11.1	114.1 ± 10.9	0.159
Mean diastolic blood pressure 3rd trimester, mmHg	70.3 ± 7.5	70.4 ± 7.5	69.4 ± 8.4	0.345
Smoking before/during pregnancy, %	35.3/13.6	35.5/13.7	32.1/12.5	0.613/0.801
Placental DNA methylation, %	3.01 ± 0.48	3.00 ± 0.46	3.22 ± 0.63	0.013
Parity number ≤1/≥2, %	75.7/24.3	75.9/24.1	72.2/27.8	0.545
s/p 2 or more miscarriages, %	6.5	6.4	8.9	0.449
Twin gestations, %	2.1	2.1	3.6	0.445
Gestational age at delivery, weeks	38.7 ± 2.1	38.7 ± 2.1	38.4 ± 1.8	0.056
Preterm birth (<37 weeks), %	10.3	10.4	8.9	0.728
Birth weight, g	3339.6 ± 634.8	3329.8 ± 627.1	3509.6 ± 742.5	0.039
AGA/SGA/LGA, %	77.7/13.0/9.4	78.6/12.9/8.6	62.5/14.3/23.2	0.001
Birth length, cm	50.6 ± 3.2	50.6 ± 3.1	50.3 ± 5.0	0.626
Child head circumference, cm	34.7 ± 1.7	34.7 ± 1.7	34.6 ± 1.8	0.719
Ponderal index, kg/m ³	25.5 ± 2.5	25.4 ± 2.5	26.5 ± 3.0	0.002
Mode of delivery (spontaneous, OVD, c-section; %)	67.1/7.4/25.5	67.9/7.7/24.4	56.4/3.6/40.0	0.030
Child sex, male/female, %	51.7/48.3	51.6/48.4	53.6/46.4	0.780
Apgar score at 5 min	9.3 ± 1.0	9.3 ± 1.0	9.3 ± 0.9	0.996
Apgar score at 10 min	9.6 ± 0.8	9.6 ± 0.8	9.5 ± 0.7	0.137
Maternal HbA1c, %	6.1 ± 0.7	5.8 ± 3.3	4.2 ± 6.6	<0.0001

Data are given as mean ± SD or percentage
^aComparison between "GDM" and "no GDM"

the beginning and in the third trimester of pregnancy (24.8 ± 5.8 vs. 23.0 ± 4.4 kg/m²; $p = 0.027$; 29.6 ± 5.3 vs. 27.5 ± 4.4 kg/m²; $p = 0.005$). Newborns of GDM mothers had a significantly increased birth weight (3509.6 ± 742.5 vs. 3329.8 ± 627.1 g; $p = 0.039$), had an increased ponderal index (26.5 ± 3.0 vs. 25.4 ± 2.5; $p = 0.002$), and were more often delivered by c-section (40.4% vs. 24.4%; $p = 0.030$). Furthermore, the distribution of appropriate (AGA), small (SGA), and large (LGA) for gestational age newborns was significantly shifted towards a higher prevalence of LGA births in GDM mothers (62.5 % AGA/14.3 % SGA/23.2 % LGA vs. 78.6 % AGA/12.9 % SGA/8.6 % LGA; $p = 0.001$). LGA was also associated with significantly increased placental DNA methylation (3.19 ± 0.55 %) compared to SGA (3.01 ± 0.43 %; $p < 0.01$) and AGA (2.99 ± 0.47 %; $p < 0.001$).

Bivariate logistic regression showed a highly significant correlation between placental DNA methylation and presence of GDM in an unadjusted model (Exp(B): 2.373; 95 % CI 1.425–3.954; $p = 0.0009$). To further categorize this relationship, quintiles of placental DNA methylation were generated (five groups of $n = 206$) and analyzed in crosstabs for the frequency distribution of gestational diabetes. Figure 2 shows a cross tabulation of placental DNA methylation ranked in quintiles and the occurrence of GDM. The frequency of GDM was evenly distributed in quintiles 1–4 with frequencies ranging between 2.9 and 5.3 %, only in the fifth quintile a significantly higher GDM frequency of 10.7 % was found (Pearson chi square 16.127; $p = 0.003$; Fig. 2). This observation was even more significant after re-stratification into two groups, the first consisting of placental DNA methylation quintiles 1–4 ($n = 824$) and the



second of methylation quintile 5 ($n = 206$) (Pearson chi-square 13.766; $p = 0.0002$; Table 2).

Table 2 shows detailed descriptive statistics of the study population according to the abovementioned stratification into lower degrees of placental DNA methylation (quintiles 1–4; $n = 824$) versus high placental DNA methylation (quintile 5; $n = 206$). There were significant differences regarding the ethnic composition of the highest methylation group vs. methylation quintiles 1–4, with more non-Caucasians in the high [21] methylation group (9.7 vs. 5.7 %; $p = 0.037$). There was a significantly higher frequency of

GDM in the highest methylation group (10.7 vs. 4.1 %; $p = 0.0002$). Moreover, a significant increase of LGA births was observed in the highest methylation group (73.0 % AGA, 12.7 % SGA, 14.2 % LGA vs. 78.8 % AGA, 13.0 % SGA, 8.2 % LGA; $p = 0.028$). Additionally, the Apgar score 10 min postnatally was significantly reduced in the highest methylation group (9.5 ± 0.8 vs. 9.6 ± 0.7 ; $p = 0.011$).

Adjusted bivariate logistic regression models

To demonstrate that a high degree of placental DNA methylation is independently associated with GDM,




Table 2 Descriptive data of the mother/child pairs grouped according to the degree of placental DNA methylation

Maternal characteristics	Degree of placental DNA methylation		p value ^a
	Quintiles 1–4 (n = 824)	Quintile 5 (n = 206)	
Maternal age, years	29.9 ± 6.0	30.3 ± 5.5	0.407
Ethnicity (Caucasian, non-Caucasian), %	94.3/5.7	90.3/9.7	0.037
Maternal height, cm	167.0 ± 6.9	166.5 ± 7.3	0.365
Body mass index before pregnancy, kg/m ²	23.2 ± 4.5	22.8 ± 4.4	0.094
Body mass index 3rd trimester, kg/m ²	27.6 ± 4.5	27.4 ± 4.3	0.801
Hypertension before/during pregnancy, %	2.0/3.5	3.4/4.9	0.200/0.443
Diabetes mellitus during pregnancy, %	4.1	10.7	0.0002
Diabetes in family, %	38.1	38.2	0.964
Mean systolic blood pressure 3rd trimester, mmHg	116.4 ± 11.0	115.3 ± 11.5	0.202
Mean diastolic blood pressure 3rd trimester, mmHg	70.4 ± 7.5	70.0 ± 7.5	0.491
Smoking before/during pregnancy, %	35.4/13.3	34.6/14.7	0.828/0.635
Placental DNA methylation, %	2.84 ± 0.32	3.71 ± 0.34	<0.0001
Parity number <2/≥2, %	76.1/23.9	73.8/26.2	0.481
s/p 2 or more miscarriages, %	6.3	7.3	0.613
Twin gestations, %	1.8	3.4	0.161
Gestational age at delivery, weeks	38.7 ± 2.1	38.8 ± 1.8	0.989
Preterm birth (<37 weeks), %	10.3	10.3	0.983
Birth weight, g	3334.8 ± 628.3	3358.5 ± 661.4	0.634
AGA/SGA/LGA, %	78.8/13.0/8.2	73.0/12.7/14.2	0.028
Birth length, cm	50.6 ± 3.1	50.5 ± 3.6	0.951
Child head circumference, cm	34.7 ± 1.7	34.6 ± 1.7	0.436
Ponderal index, kg/m ³	25.5 ± 2.5	25.5 ± 2.7	0.943
Mode of delivery (spontaneous, OVD, c-section; %)	66.2/8.1/25.8	70.1/5.2/24.7	0.387
Child sex, male/female, %	52.3/47.7	49.8/50.2	0.522
Apgar score at 5 min	9.3 ± 1.0	9.2 ± 1.1	0.084
Apgar score at 10 min	9.6 ± 0.7	9.5 ± 0.8	0.011
Maternal HbA1c, m	43 ± 7.7	45 ± 8.7	0.257

Data are given as mean ± SD or percentage

^aComparison between "Quintiles 1–4" and "Quintile 5"

adjusted bivariate logistic regression models were calculated. To account for confounding, the models were adjusted for available parameters known to be risk factors for GDM [6]. Risk factors included in the models were maternal age, BMI at the beginning of pregnancy, a history of recurrent (≥2) miscarriages (yes; no), ethnic background (Caucasian; non-Caucasian), and family history of type 2 diabetes (yes; no). Model A used these confounders together with placental DNA methylation as a continuous variable. In this model, placental DNA methylation was significantly associated with the presence of GDM ((exp)B = 2.408; 95 % CI 1.427–4.063; $p = 0.001$; Table 3). In model B, placental DNA methylation stratified into the before mentioned two groups of high placental DNA methylation

(quintile 5; $n = 206$) and lower degrees of placental DNA methylation (quintiles 1–4; $n = 824$) was used. Grouped placental DNA methylation was associated with the presence of GDM even more significantly ((exp)B = 2.999; 95 % CI 1.691–5.316; $p = 0.0002$; Table 3).

Adjusted ANCOVA model

To demonstrate that GDM is independently associated with global placental DNA methylation, an ANCOVA model was calculated and adjusted for predictors of DNA methylation evinced in previous methylation studies [25, 26]. These factors included smoking status before pregnancy (yes/no), ethnic background (Caucasian; non-Caucasian), sex of the child (male/female), and age

Table 3 Model A: logistic regression investigating an association between placental DNA methylation and GDM; model B: logistic regression investigating an association between placental DNA methylation grouped into the fifth quintile ($n = 206$) versus quintiles 1–4 ($n = 824$) and GDM

Model A	B	S.E.	Sig.	Exp(B)	95 % CI for Exp(B)	
Constant	-8.647 ± 1.589; $p < 0.0001$				Lower	Upper
Maternal age, years	0.061	0.026	0.017	1.063	1.011	1.118
BMI beginning of pregnancy, kg/m ²	0.067	0.025	0.008	1.069	1.018	1.124
S/p 2 or more miscarriages, %	-0.128	0.502	0.798	0.880	0.329	2.351
Ethnicity (Caucasian, other)	-0.111	0.558	0.842	0.895	0.300	2.669
Diabetes in family (yes/no)	-0.318	0.289	0.271	0.728	0.413	1.281
Placental DNA methylation, %	0.879	0.267	0.001	2.408	1.427	4.063
Model B	B	S.E.	Sig.	Exp(B)	95 % CI for Exp(B)	
Constant	-5.240 ± 1.275; $p < 0.0001$				Lower	Upper
Maternal age, years	0.061	0.026	0.017	1.063	1.011	1.118
BMI beginning of pregnancy, kg/m ²	0.073	0.025	0.004	1.076	1.024	1.13
S/p 2 or more miscarriages, (%)	-0.143	0.501	0.775	0.867	0.325	2.314
Ethnicity (Caucasian, other)	-0.139	0.554	0.802	0.87	0.294	2.579
Diabetes in family (yes/no)	-0.314	0.289	0.277	0.731	0.415	1.286
Placental DNA methylation (grouped)	1.098	0.292	0.0002	2.999	1.691	5.316

of the mother. GDM [73] is the strongest predictor of global placental DNA methylation ($B = 0.215$; 95 % CI 0.087–0.342; $p = 0.001$; Table 4) in this model. Additionally, the maternal smoking status before pregnancy was also significantly associated [65] with global placental DNA methylation ($B = -0.064$; 95 % CI -0.126–0.002; $p = 0.044$; Table 4). Ethnicity of the mother, sex of the child, and maternal age showed no association with global placental DNA methylation (Table 4).

Discussion

The current study showed [36] a normally constituted cohort of delivering woman that there is a significant positive correlation between the degree of placental DNA methylation and GDM, i.e., higher levels of placental 5mC are associated with a higher frequency of GDM. Analyzing the mean levels of placental 5mC according to the presence or absence of GDM showed significantly

higher mean values in GDM mothers. For a better understanding of the relationship between methylation and the risk for GDM, mothers were ranked in quintiles according [21] to the degree of placental DNA methylation. This revealed a significantly elevated frequency of GDM in the fifth quintile. Calculating different bivariate logistic regression models with placental DNA methylation as continuous and categorical variable, adjusted for known risk factors of GDM, underlined an independent association between placental DNA hypermethylation and GDM. An ANCOVA model adjusted for known factors influencing DNA methylation further substantiated the independent association between global placental DNA hypermethylation and GDM.

One limitation of the current study is that no large data sets of continuous variables describing GDM were available, only categorical variables displaying the final diagnosis. Yet, measured term HbA1c concentrations in

Table 4 ANCOVA analysis of the interaction between factors known to influence global DNA methylation, GDM, and global placental DNA methylation

Dependent variable: DNA methylation; $r^2 = 0.016$	B	S.E.	Power	Sig.	95 % CI for B	
					Lower	Upper
Intercept	3.06	0.091	1.000	<0.0001	2.881	3.239
GDM (yes/no)	0.215	0.065	0.911	0.001	0.087	0.342
Smoking before pregnancy (yes/no)	-0.064	0.032	0.521	0.044	-0.126	-0.002
Ethnicity (Caucasian, other)	0.112	0.061	0.457	0.064	-0.007	0.231
Sex of the child (male/female)	-0.032	0.03	0.191	0.279	-0.09	0.026
Maternal age, years	0.000	0.003	0.05	0.955	-0.005	0.005

a subset of mothers ($n = 94$), which were significantly elevated in GDM mothers, reinforced a correct diagnosis of GDM. Another limitation of this study is the usage of placental tissue without focusing on a specific placental cell type. Given the large sample size (>1000 placenta samples), purification of specific placental cell types was not feasible. However, it was shown by MethylC-seq analysis that global methylation in whole rhesus placental tissue was almost identical compared to isolated rhesus trophoblast cell methylation with a correlation of 0.89 [21]. Next to the mentioned limitations, this study exhibits several strengths. **To the best of our knowledge, it is by now the largest study** of its kind analyzing placental DNA methylation and clinical readouts in 1030 mothers. Moreover, it is the first study that uses a robust quantitative assessment of placental global DNA methylation, employing the current gold standard LC-MS/MS [24]. All other studies investigating placental DNA methylation so far were either small, employed only semiquantitative methods of measuring global DNA methylation, or were focused on specific DNA methylation [9–12, 27]. Given the absence of studies with a comparable study design in regard to sample size, analyzed tissue, and the method of global DNA methylation assessment, interpretation of the results of the current study in context with available literature warrants caution.

Average levels of global placental DNA methylation were 3.00 ± 0.46 % in uncomplicated pregnancies. This is in agreement with another study analyzing global placental DNA methylation using HPLC, also demonstrating global DNA hypomethylation in comparison to average global DNA methylation levels observed in somatic tissues [28].

The current study demonstrated **a positive association between GDM and global placental DNA methylation**. **Withstanding, a previous preliminary study by Nomura et al. showed a negative association between global placental DNA methylation and GDM** [9]. However, as only 50 placenta samples were analyzed for global DNA methylation, the observed difference in results is most likely attributable to the ~20-fold smaller study size. Additionally, the semiquantitative luminometric methylation assay was used for the measurement of global DNA methylation, which was shown to be outperformed by other approaches of global DNA methylation assessment, especially regarding inter-assay comparability [9, 24, 29].

Two studies, investigating placental DNA methylation in GDM using the Illumina Infinium 450K BeadChips array, found a predominance of hypermethylation at methylation variable positions in GDM exposed placental samples [11, 12]. However, such arrays only cover about ~1.5 % of all genomic CpGs [14]. Therefore, the results of these studies have limited value in discussing the current observations [14].

Several clinical studies, investigating **global DNA methylation in type 2 diabetes** showed higher levels of **global DNA methylation in different types of peripheral blood cells** of diabetic patients [30–36]. Global methylation in these studies was assessed by LC/MS-MS [30, 33–35] or LC/MS-MS validated methods [31] or by measuring surrogate parameters of global DNA methylation like LINE-1 or Alu elements [32, 36]. The analysis of global DNA methylation in leukocytes is a well used method in epidemiologic studies to display associations between global DNA methylation and disease [35, 37, 38]. However, whether changes in global leukocyte DNA methylation associated with an insult (e.g., diabetes) also reflect aligned methylation changes in other tissues remains elusive. Nevertheless, a general hypothesis raised by Zhao et al., speculating that a putative link between global DNA hypermethylation and diabetes could be genomic instability, might also apply for findings of the current study [32]. The hypothesis is supported by findings of other studies [39–41], and there is ample amount of evidence that genomic instability is not only a hallmark of cancer but also associated with insulin resistance [42–44]. An underlying factor bearing implications for both genomic instability and DNA hypermethylation **might be oxidative stress**. Literature suggests that **oxidative stress is involved in the development of metabolic diseases** [45]. Diabetes itself **is associated with increased oxidative stress, and it** is well described that oxidative stress can induce DNA damage, another important factor in the development of diabetes [43, 45–47]. It was also shown that reactive oxygen species regulate the activity of DNA methyltransferases and catalyze the methylation of DNA [48, 49]. Moreover, it was demonstrated in animal models that an upregulation of the activity or the expression of DNA methyltransferases is observed in different types of diabetes [48, 50, 51]. Data from these recent animal experiments support a positive association between a diabetic metabolic state and global DNA methylation and additionally delineated putative mechanisms, connecting diabetes, oxidative stress, and global DNA hypermethylation [50, 51]. Zhong et al. have shown in a streptozotocin animal model of gestational diabetes that maternal diabetes induces an increased expression of DNA methyltransferases, **increased DNA methyltransferase activity, and increased global DNA methylation (measured by MethylFlash Methylated DNA Quantification Kit** which analyzes global 5mC content) in E8.75 embryos. Notably, treatment with the polyphenol epigallocatechin gallate, which was shown to exert anti-oxidative effects and to inhibit DNA methyltransferase activity, abrogated these changes [51–53].

Conclusions

In summary, this study provides the first large scale evidence that placental global DNA hypermethylation is

associated with GDM independent of established risk factors. The results of the study are in agreement with other studies [60] however, many of the comparable studies investigated DNA methylation in type 2 diabetes, in other organs than the placenta or by different methods of global DNA methylation assessment. Nevertheless, there is substantial evidence in literature from both clinical and preclinical experimental studies supporting an association between a diabetic metabolic state and global DNA hypermethylation. The results of the current study have to be confirmed using comparable methods, to substantiate our understanding of global DNA methylation involvement in disease. In general, a harmonization of applied methodology for the measurement of global DNA methylation is warranted. Differently designed studies will be needed to demonstrate a causal relationship between global DNA hypermethylation and GDM and to elucidate the still very elusive question whether aberrant global DNA methylation is involved in the pathogenesis of GDM or a consequence of this disease.

Methods

Ethics consent, and permissions

The study was approved by the ethics committee of the university hospital Charité, Berlin, Germany. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. Written, informed consent was obtained from all partaking mothers prior to data collection.

Clinical study

This observational all-comers study included 1063 mothers delivering at the obstetrics department of Campus Charité Mitte, Berlin, Germany. Structured interviews were performed with the partaking mothers. Eleven mothers with overt diabetes before pregnancy, nine cases of preeclampsia, and 13 cases with incomplete data of the most important variables and confounders were excluded from the statistical analyses. Given a potential overlap regarding pathophysiological processes leading to preeclampsia and GDM and the low sample number of preeclamptic placentas in the current study, it stood to reason to exclude mother with preeclampsia [9, 54]. In total, 1030 mothers were included into the statistical analyses. The majority of mothers ($n = 963$; 93.5 %) were of Caucasian ethnicity, while 67 mothers (6.5 %) had other ethnic backgrounds. Data from the "Mutterpass" documenting the results of follow ups during pregnancy were also collected. The following data were available for the dataset: age, ethnicity, body height, body mass index (BMI) at the beginning of pregnancy, body mass index (BMI) at the third trimester of pregnancy, parity, diabetes mellitus before or during pregnancy, family history of diabetes, incidence of hypertension before and during

pregnancy, smoking before and during pregnancy, systolic and diastolic blood pressure measurements recorded during pregnancy, and in a small subset ($n = 94$) of mothers, maternal HbA1c levels at term. GDM was screened and assessed in all mothers according to the practice guideline of the German Diabetes Association (DGG) and the German Association for Gynaecology and Obstetrics (DGOG) [55]. Biometric data of the newborn were collected during the routine postnatal examination. Gestational age at delivery was based on the last menstrual period, anamnestically assessed during the first pregnancy examination. The following data of the newborn were added to the database: birth weight, birth length, head circumference, child sex, Apgar score 5 min postnatally and Apgar score 10 min postnatally. A standardized placenta sample—1 complete cotyledon (cross section of all layers) from similar locations—was collected and immediately frozen and stored at -20°C . For the extraction of DNA a sample of chorionic villi was obtained from the whole cotyledon.

Data were analyzed using SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA). Depending on normal distribution, unpaired t test or Mann-Whitney U test was used when comparing mean values of two groups. For the comparison of categorical variable distribution, chi-square test was used. Bivariate logistic regression was used to analyze the relationship of continuous and categorical data with a categorical outcome, to confirm relevant confounding variables that had an independent influence, and to adjust for these in different statistical models. To calculate associations between a continuous dependent variable and both categorical and continuous independent variables, ANCOVA models were used. Bar graphs were calculated and compiled with Graphpad Prism 5 (GraphPad Software, Inc., La Jolla, California, USA). Probability values <0.05 were considered significant. The authors had full access to the data and take full responsibility for its integrity.

Analysis of DNA methylation

DNA was extracted using a QIAamp DNA Mini Kit from Qiagen (Milden, Germany) together with a RNase A digestion according to the manufacturer's protocol. The concentration and quality of the RNA-free DNA solution were determined by a NanoDrop ND-1000 spectrophotometer. DNA hydrolysis was carried out using DNA Degrade Plus from Zymo Research (Freiburg, Germany). Briefly, 1 μg of genomic DNA was mixed with 39 μL 10 \times DNA Degradase Reaction Buffer, and 1 μL DNA Degradase Plus and filled up with water to a volume of 25 μL . DNA hydrolysis was stopped after 4 h at 37°C by adding 75 μL of 0.1 % formic acid. Agarose gel electrophoresis using 200 ng of the digested DNA was employed in order to control the completeness of digestion. Seventy microliters of the hydrolysed DNA

samp³⁸ were further diluted with 280 μ L 0.1 % formic acid to yield a final concentration of 2 ng dig²⁷ed DNA/ μ L. DNA methylation was assessed by liquid chromatography-electrospray ionization/multi-stage mass spectrometry (LC-ESI/MS²⁵) technique as described previously [56]. LC-ESI/MS/MS was performed with an Agilent 1200 series HPLC system connected to an Agilent 6530 Accurate-Mass Q-TOF instrument with Jet Stream-Interface (Waldbronn, Germany). For chromatogra⁵⁶ separation a Waters (Milford, MA) X-BridgeTM C¹⁸ 4.6 mm \times 150 mm (3.5- μ m partid⁵⁵e) protected by a Waters X-BridgeTM C¹⁸ 4.6 mm \times 20 mm guard column (5- μ m particle size) was used. 0.1 % formic acid in water (solvent A) and 0.1 % formic acid in methanol (solvent B) were chosen as ²⁶mobile phases. The linear gradient elution was 4–20 % of solvent B in 10 min at a constant flow rate of 0.5 mL/min. Fifty microliters of the diluted DNA hydrolysis samples, typically containing 100-ng digested DNA, were injected. The optimized ESI-MS/MS parameters in the posit²²ion mode were as follows: gas temperature, 250 °C; drying gas flow, 8 L/min; nebulizer pressure, 60 psig; sheat gas temperature, 300 °C; capillary voltage 4000 V; and collision energy 7 V for dC, 13 V for 5mdC, and 10 V for dG. Quantification was accomplished in selected read¹¹ monitoring (SRM) mode by monitoring a transition pair of m/z 228.0979/112.0505 for dC, m/z 242.1135/126.0662 for 5mdC, and m/z 268.1040/152.0780 for dG, which was used as an internal standard for the measurement. The scan time was 333 ms for each pair. The deo⁵⁴bonucleosides 2'-deoxyguanosine (dG) monohydrate, 5-methyl-2'-deoxycytidine (5mdC) and 2'-deoxycytidine (dC) were purchased from ABCR (Karlsruhe, Germany). Hering sperm DNA was obtained from Sigma-Aldrich (Hamburg, Germany). Nuclease-free water used for DNA extraction was purchased from Roth (Karlsruhe, Germany). LC-MS-grade water, methanol, and formic acid were purchased from V⁸R international, Inc. (Dresden, Germany). The global ⁸level of DNA methylation was calculated as the percentage of ⁵³NA methylation as follows: DNA methylation % = $\frac{5\text{-methyl-2'-deoxycytidine (5mdC)}}{5\text{-methyl-2'-deoxycytidine (5mdC)} + 2'\text{-deoxycytidine (dC)}} \times 100$ %.

Abbreviations

5mC, 5-methylcytosine; AGA, appropriate for gestational age; DGG³¹ German Diabetes Association; DGGG German Associati⁵²; Gynaecology and Obstetrics; GDM, gestational diabetes mellitus; IADR¹¹ International Association of Diabetes in Pregnancy Study Group; LC-MS/MS, Liquid chromatography tandem mass spectrometry; LGA, large for gestational age; OVD, operative vaginal delivery; SGA, small for gestational age

Acknowledgements

Not applicable.

Funding

This study was partially funded by the Deutsche Forschungsgemeinschaft (DFG grant No. Ho1665/5-2 to Prof. Hocher).

Availability of data and materials

The dataset contains indirect identifiers. As there is some risk of identification, the dataset was not approved for publication in a freely accessible manner by the local ethics committee.

Authors' contributions

BH was responsible for the clinical study design. TP, TS, and BH conducted the clinical study, edited the manuscript, and contributed to the discussion. SEDP and CN performed the measurements of global DNA methylation and edited the manuscript. SEDP contributed to the discussion. CR wrote the manuscript and analyzed the data. BK coordinated the measurement of global DNA, edit³ the manuscript, and contributed to the discussion. BH is the guarantor of this work and had full access to all the data in the study and takes res¹ponsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethi⁶ approval and consent to participate

The study was approved by the institutional ethics committee of the ¹⁶ersity hospital Charité, Berlin, Germany. All clinical investigations were conducted ⁸according to the principles expressed in the Declaration of Helsinki. Written, informed consent was obtained from all partaking mothers prior to data collection.

Author details

¹Department of Experimental Nutritional Medicine, Institute of Nutritional Science, University of Potsdam, Arthur-Scheunert-Allee ⁴⁴116, Nuthetal, Potsdam 14558, Germany. ²Department of Toxicology, Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany. ³Department of Nephrology, Campus Charité Mitte, University Hospital Charité, Berlin, Germany. ⁴Center for Cardiovascular Research (CCR), Campus Charité Mitte, University Hospital Charité, Berlin, Germany. ⁵Faculty of Biotechnology, University of Surabaya, Surabaya, Indonesia. ⁶Diaverum Deutschland, Potsdam, Ger³⁴y. ⁷Institut für Laboratoriumsmedizin, Berlin, Germany. ⁸Department of Basic Medicine, Medical College of Hunan Normal University, Changsha, China.

Received: 26 April 2016 Accepted: 11 July 2016

Published online: 26 July 2016

References

- Lappas M, Hiden U, Desoye G, Froehlich J, Hauguel-de Mouzon S, Jaberbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. *Antioxid Redox Signal*. 2011;15:3061–100.
- Schneider S, Bock C, Wetzel M, Maul H, Loerbroks A. The prevalence of gestational diabetes in advanced economies. *J Perinat Med*. 2012;40:511–20.
- Coustan DR. Gestational diabetes mellitus. *Clin Chem*. 2013;59:1310–21.
- Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Aktry WM, et al. Screening and diagnosing gestational diabetes mellitus. Evidence Report/Technology Assessment no. 210. AHRQ Publication no. 12(13)-E021-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
- Gauster M, Desoye G, Tötsch M, Hiden U. The placenta and gestational diabetes mellitus. *Curr Diab Rep*. 2012;12:16–23.
- Reece EA, Leguizamón G, Wiznitzer A. Gestational diabetes: the need for a common ground. *Lancet*. 2009;373:1789–97.
- Schäfer-Graf P-DD med UM, Kautzky-Willer U-PD med A. Diabetes mellitus und Schwangerschaft. In: Schneider PD med H, Husslein U-PD med P-W, Schneider U-PD med KTM, editors. *Die Geburtshilfe*. Berlin: Springer; 2011. p. 435–56.
- Gabbay-Benziv R, Baschat AA. Gestational diabetes as one of the "great obstetrical syndromes"—the maternal, placental, and fetal dialog. *Best Pract Res Clin Obstet Gynaecol*. 2015;29:150–5.
- Nomura Y, Lambertini L, Rialdi A, Lee M, Mystal EY, Grabie M, et al. Global methylation in the placenta and umbilical cord blood from pregnancies with maternal gestational diabetes, preeclampsia, and obesity. *Reprod Sci*. 2014;21:131–7.

10. Bouchard L, Hivert M-F, Guay S-P, St-Pierre J, Perron P, Brisson D. Placental adiponectin gene DNA methylation levels are associated with mothers' blood glucose concentration. *Diabetes*. 2012;61:1272–80.
11. Ruchat S-M, Houde A-A, Voisin G, St-Pierre J, Perron P, Ballargeon J-P, et al. Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. *Epigenetics*. 2013;8:935–43.
12. Finer S, Mathews C, Lowe R, Smart M, Hillman S, Foo L, et al. Maternal gestational diabetes is associated with genome-wide DNA methylation variation in placenta and cord blood of exposed offspring. *Hum Mol Genet*. 2015;24(11):3021–9.
13. Binder AM, LaRocca J, Lesseur C, Marsit CJ, Michels KB. Epigenome-wide and transcriptome-wide analyses reveal gestational diabetes is associated with alterations in the human leukocyte antigen complex. *Clin Epigenetics*. 2015;7:79.
14. Busche S, Shao X, Caron M, Kwan T, Allum F, Cheung WA, et al. Population whole-genome bisulfite sequencing across two tissues highlights the environment as the principal source of human methylome variation. *Genome Biol*. 2015;16:290.
15. Patrusev LI, Kovalenko TF. Functions of noncoding sequences in mammalian genomes. *Biochemistry (Mosc)*. 2014;79:1442–69.
16. Gregory TR. Synergy between sequence and size in large-scale genomics. *Nat Rev Genet*. 2005;6:699–708.
17. Gelfman S, Cohen N, Yearim A, Ast G. DNA-methylation effect on cotranscriptional splicing is dependent on GC architecture of the exon-intron structure. *Genome Res*. 2013;23:789–99.
18. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation. *Trends Genet*. 2015;31:274–80.
19. Reddington JP, Pennings S, Meehan RR. Non-canonical functions of the DNA methylome in gene regulation. *Biochem J*. 2013;451:13–23.
20. Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. *Biology (Basel)* [Internet]. 2016 [cited 2016 Jun 11];5. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810160/>
21. Schroeder DJ, Jayashankar K, Douglas KC, Thirkill TL, York D, Dickinson PJ, et al. Early developmental and evolutionary origins of gene body DNA methylation patterns in mammalian placentas. *PLoS Genet*. 2015;11, e1005442.
22. Chatterjee A, Macaulay EC, Rodger EJ, Stockwell PA, Parry MF, Roberts HE, Slatter TL, Hung NA, Devenish CJ, Morrison IM. Placental Hypomethylation Is More Pronounced in Genomic Loci Devoid of Retroelements. *G3 (Bethesda)*. 2016;6(7):1911–21. doi:10.1534/g3.116.030379.
23. Bianco-Miotto T, Mayne BT, Buckberry S, Breen J, Lopez CMR, Roberts CT. Recent progress towards understanding the role of DNA methylation in human placental development. *Reproduction*. 2016;152:R23–30.
24. Liu J, Hesson LB, Ward RL. Liquid Chromatography Tandem Mass Spectrometry for the Measurement of Global DNA Methylation and Hydroxymethylation. *Journal of Proteomics & Bioinformatics* [Internet]. Available from: http://www.omicsonline.org/proteomics-bioinformatics-abstract.php?abstract_id=15772
25. Tajuddin SM, Amaral AFS, Fernandez AF, Rodriguez-Rodero S, Rodriguez RM, Moore LE, et al. Genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA. *Environ Health Perspect*. 2013;121:650–6.
26. Boeke CE, Baccarelli A, Kleinman KP, Burris HH, Litonjua AA, Rifas-Shiman SL, et al. Gestational intake of methyl donors and global LINE-1 DNA methylation in maternal and cord blood: prospective results from a folate-replete population. *Epigenetics*. 2012;7:253–60.
27. Lesseur C, Armstrong DA, Paquette AG, Li Z, Padbury JF, Marsit CJ. Maternal obesity and gestational diabetes are associated with placental leptin DNA methylation. *Am J Obstet Gynecol*. 2014;211(6):654.e1–9.
28. Fuke C, Shimabukuro M, Petronis A, Sugimoto J, Oda T, Miura K, et al. Age related changes in 5-methylcytosine content in human peripheral leukocytes and placentas: an HPLC-based study. *Ann Hum Genet*. 2004;68:196–204.
29. Lisanti S, Omar WAW, Tomaszewski B, De Prins S, Jacobs G, Koppen G, et al. Comparison of methods for quantification of global DNA methylation in human cells and tissues. *PLoS One*. 2013;8.
30. Maghbooli Z, Larijani B, Emamgholipour S, Amini M, Keshtkar A, Pasalar P. Aberrant DNA methylation patterns in diabetic nephropathy. *J Diabetes Metab Disord*. 2014;13:69.
31. Simar D, Verstehe S, Donkin I, Liu J, Hesson L, Nylander V, et al. DNA methylation is altered in B and NK lymphocytes in obese and type 2 diabetic human. *Metab Clin Exp*. 2014;63:1188–97.
32. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. *Diabetes*. 2012;61:542–6.
33. Maghbooli Z, Hossein-Nezhad A, Larijani B, Amini M, Keshtkar A. Global DNA methylation as a possible biomarker for diabetic retinopathy. *Diabetes Metab Res Rev*. 2014;31(2):183–9.
34. Maghbooli Z, Hossein-Nezhad A, Larijani B, Pasalar P, Keshtkar AA. Association between alterations in global DNA methylation and predisposing factors in diabetes: a high pressure liquid chromatography based study. *Minerva Med*. 2015;106:221–31.
35. Maghbooli Z, Hossein-Nezhad A, Larijani B, Amini M, Keshtkar A. Global DNA methylation as a possible biomarker for diabetic retinopathy. *Diabetes Metab Res Rev*. 2015;31:183–9.
36. Pearce MS, McConnell JC, Potter C, Barrett LM, Parker L, Mathers JC, et al. Global LINE-1 DNA methylation is associated with blood glycaemic and lipid profiles. *Int J Epidemiol*. 2012;41:210–7.
37. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. *Epigenetics*. 2011;6:828–37.
38. Kim YO, Li C, Sun BK, Kim JS, Lim SW, Choi BS, et al. Preconditioning with 1,25-dihydroxyvitamin D3 protects against subsequent ischemia-reperfusion injury in the rat kidney. *Nephron Exp Nephrol*. 2005;100:e85–94.
39. Walters RJ, Williamson EJ, English DR, Young JP, Rosty C, Clendenning M, et al. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer. *Epigenetics*. 2013;8:748–55.
40. Neale RE, Clark PJ, Fawcett J, Fritschi L, Nagler BN, Risch HA, et al. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and pancreatic cancer. *Cancer Epidemiol*. 2014;38:576–82.
41. Liao LM, Brennan P, van Bemmelen DM, Zaridze D, Matveev V, Janout V, et al. LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. *PLoS One*. 2011;6.
42. Moran LJ, Noakes M, Clifton PM, Norman RJ, Fenech MF. Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. *Mutat Res*. 2008;639:55–63.
43. Attia SM, Helal GK, Alhaider AA. Assessment of genomic instability in normal and diabetic rats treated with metformin. *Chem Biol Interact*. 2009;180:296–304.
44. Binici DN, Karaman A, Coşkun M, Oğlu AU, Uçar F. Genomic damage in patients with type-2 diabetes mellitus. *Genet Couns*. 2013;24:149–56.
45. Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. *Life Sci*. 2016;148:183–93.
46. Milic M, Frustaci A, Del Bufalo A, Sánchez-Alarcón J, Valencia-Quintana R, Russo P, et al. DNA damage in non-communicable diseases: a clinical and epidemiological perspective. *Mutat Res*. 2015;776:118–27.
47. Dong D, Yu J, Wu Y, Fu N, Villela NA, Yang P. Maternal diabetes triggers DNA damage and DNA damage response in neurulation stage embryos through oxidative stress. *Biochem Biophys Res Commun*. 2015;467:407–12.
48. Wei D, Loeken MR. Increased DNA methyltransferase 3b (Dnmt3b)-mediated CpG island methylation stimulated by oxidative stress inhibits expression of a gene required for neural tube and neural crest development in diabetic pregnancy. *Diabetes*. 2014;63:3512–22.
49. Hai Z, Zuo W. Aberrant DNA methylation in the pathogenesis of atherosclerosis. *Clin Chim Acta*. 2016;456:69–74.
50. Williams KT, Schallinske KL. Tissue-specific alterations of methyl group metabolism with DNA hypermethylation in the Zucker (type 2) diabetic fatty rat. *Diabetes Metab Res Rev*. 2012;28:123–31.
51. Zhong J, Xu C, Reece EA, Yang P. The green tea polyphenol EGCG alleviates maternal diabetes-induced neural tube defects by inhibiting DNA hypermethylation. *Am J Obstet Gynecol*. 2016. doi:10.1016/j.ajog.2016.03.009.
52. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (–)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res*. 2003;63:7563–70.
53. Legeay S, Rodier M, Fillon L, Faure S, Clerc N. Epigallocatechin gallate: a review of its beneficial properties to prevent metabolic syndrome. *Nutrients*. 2015;7:5443–68.
54. Liu L, Zhang X, Rong C, Rui C, Ji H, Qian Y, et al. Distinct DNA methylomes of human placentas between pre-eclampsia and gestational diabetes mellitus. *Cell Physiol Biochem*. 2014;34:1877–89.
55. Kleinwechter H, Schäfer-Graf U, Bühner C, Hoesli I, Kainer F, Kautzky-Willer A, et al. Gestational diabetes mellitus (GDM) diagnosis, therapy and follow-up care. *Exp Clin Endocrinol Diabetes*. 2014;122:395–405.
56. Dwi Putra SE, Neuber C, Reichetzeder C, Hoehner B, Kleuser B. Analysis of genomic DNA methylation levels in human placenta using liquid chromatography-electrospray ionization tandem mass spectrometry. *Cell Physiol Biochem*. 2014;33:945–52.

eased_global_placental_DNA_methylation_levels_are_associate.

ORIGINALITY REPORT

15%

SIMILARITY INDEX

4%

INTERNET SOURCES

12%

PUBLICATIONS

6%

STUDENT PAPERS

PRIMARY SOURCES

1	Rymbay Kaliyev, Timur Lesbekov, Serik Bekbossynov, Zhuldyz Nurmykhametova et al. "Heart transplantation of patients with ventricular assist devices: impact of normothermic ex-vivo preservation using organ care system compared with cold storage", Research Square, 2020 Publication	<1%
2	www.researchprotocols.org Internet Source	<1%
3	Submitted to Far Eastern University Student Paper	<1%
4	Submitted to Canterbury Christ Church University Student Paper	<1%
5	Submitted to University of Arizona Student Paper	<1%
6	Submitted to Salisbury University Student Paper	<1%
7	Submitted to University of Kentucky	

<1%

8

Walters, Rhiannon J., Elizabeth J. Williamson, Dallas R. English, Joanne P. Young, Christophe Rosty, Mark Clendenning, Michael D. Walsh, Susan Parry, Dennis J. Ahnen, John A. Baron, Aung Ko Win, Graham G. Giles, John L. Hopper, Mark A. Jenkins, and Daniel D. Buchanan. "Association between hypermethylation of DNA repetitive elements in white blood cell DNA and early-onset colorectal cancer", *Epigenetics*, 2013.

<1%

Publication

9

Shi-Min Hu, Meng-Shi Chen, Hong-Zhuan Tan. "Maternal serum level of resistin is associated with risk for gestational diabetes mellitus: A meta-analysis", *World Journal of Clinical Cases*, 2019

<1%

Publication

10

prkdecg.xyz

Internet Source

<1%

11

Zhongfa Liu, Jiejun Wu, Zhiliang Xie, Shujun Liu et al. "Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry", *Analytical Biochemistry*, 2009

<1%

Publication

12

Gabbay-Benziv, Rinat, and Ahmet A. Baschat. "Gestational diabetes as one of the "great obstetrical syndromes" – the maternal, placental, and fetal dialog", Best Practice & Research Clinical Obstetrics & Gynaecology, 2015.

Publication

<1%

13

Kavita Nanda. "Terbutaline pump maintenance therapy after threatened preterm labor for preventing preterm birth", Cochrane Database of Systematic Reviews Reviews, 10/21/2002

Publication

<1%

14

Jorge Andrés Delgado-Ron, Patricio López-Jaramillo, Mohammad Ehsanul Karim. "Sodium intake and high blood pressure among adults on caloric restriction: a multi-year cross-sectional analysis of the U.S. Population, 2007-2018", Cold Spring Harbor Laboratory, 2021

Publication

<1%

15

Submitted to 60556

Student Paper

<1%

16

S. Pauwels, I. Truijen, M. Ghosh, R. C. Duca et al. "The effect of paternal methyl-group donor intake on offspring DNA methylation and birth weight", Journal of Developmental Origins of Health and Disease, 2017

Publication

<1%

17

R. Scarpato. "Spontaneous and bleomycin-induced chromosome damage in non cancer thyroid patients", *European Journal of Clinical Investigation*, 12/2009

Publication

<1%

18

M. Gauster, G. Desoye, M. Tötsch, U. Hiden. "The Placenta and Gestational Diabetes Mellitus", *Current Diabetes Reports*, 2011

Publication

<1%

19

eje.bioscientifica.com

Internet Source

<1%

20

Submitted to University of Durham

Student Paper

<1%

21

Jakub Rosik, Bartosz Szostak, Filip Machaj, Andrzej Pawlik. "The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitus", *Annals of Human Genetics*, 2019

Publication

<1%

22

Aránzazu Marín, Keith Burton, Alfonso Rivera-Sagredo, Alfonso Espada et al. "Optimization and Standardization of Liquid Chromatography-Mass Spectrometry Systems for the Analysis of Drug Discovery Compounds", *Journal of Liquid Chromatography & Related Technologies*, 2007

Publication

<1%

23

Sibel Ozler, Efser Oztas, Basak Gumus Guler, Ozcan Erel, Ali Turhan Caglar, Merve Ergin, Dilek Uygur, Nuri Danisman. "Are serum levels of ADAMTS5, TAS and TOS at 24–28 gestational weeks associated with adverse perinatal outcomes in gestational diabetic women?", *Journal of Obstetrics and Gynaecology*, 2019

Publication

<1%

24

Aneta Słabuszewska-Józwiak, Marta Włodarczyk, Michał Ciebiera, Joanna Zwolińska et al. "Placental DNA methylation in caesarean sections – a pilot study", *Archives of Medical Science*, 2020

Publication

<1%

25

Submitted to Ming Chuan University

Student Paper

<1%

26

www.mcponline.org

Internet Source

<1%

27

E. Vlassaks, A. W. D. Gavilanes, V. Bieghs, A. Reinartz et al. "Antenatal exposure to chorioamnionitis affects lipid metabolism in 7-week-old sheep", *Journal of Developmental Origins of Health and Disease*, 2012

Publication

<1%

28

Submitted to The University of Manchester

Student Paper

<1%

29

Sujin Kim, Yoon Hee Cho, Inae Lee, Wonji Kim et al. "Prenatal exposure to persistent organic pollutants and methylation of LINE-1 and imprinted genes in placenta: A CHECK cohort study", Environment International, 2018

Publication

<1%

30

Maria Stoikou, Franco Grimolizzi, Stavros Giaglis, Günther Schäfer, Shane Vontelin van Breda, Irene Mathilde Hoesli, Olav Lapaire, Evelyn A. Huhn, Paul Hasler, Simona W. Rossi, Sinuhe Hahn. "Gestational Diabetes Mellitus Is Associated with Altered Neutrophil Activity", Frontiers in Immunology, 2017

Publication

<1%

31

Submitted to University of Shajrah

Student Paper

<1%

32

Submitted to University of Stellenbosch, South Africa

Student Paper

<1%

33

Submitted to University of Nottingham

Student Paper

<1%

34

insights.ovid.com

Internet Source

<1%

35

meridian.allenpress.com

Internet Source

<1%

36

Molecular mechanisms and physiology of disease, 2014.

Publication

<1%

37

medcraveonline.com

Internet Source

<1%

38

Miho M. Suzuki, Tomoko Mori, Noriyuki Satoh. "The *Ciona intestinalis* cleavage clock is independent of DNA methylation", Genomics, 2016

Publication

<1%

39

William M. Webb, Richard G. Sanchez, Gabriella Perez, Anderson A. Butler et al. "Dynamic association of epigenetic H3K4me3 and DNA 5hmC marks in the dorsal hippocampus and anterior cingulate cortex following reactivation of a fear memory", Neurobiology of Learning and Memory, 2017

Publication

<1%

40

Graham MacLeod, Danielle A. Bozek, Nishani Rajakulendran, Vernon Monteiro et al. "The functional genomic circuitry of human glioblastoma stem cells", Cold Spring Harbor Laboratory, 2018

Publication

<1%

41

J. Mendoza- Perez, J. Gu, L. A. Herrera, N. M. Tannir, S. F. Matin, J. A. Karam, M. Huang, D. W. Chang, C. G. Wood, X. Wu. "Genomic DNA

<1%

Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study", Clinical Cancer Research, 2015

Publication

42

Xinyi Zhang, Lina Bai, Haiqin Ren, Xinyu Liu, Shuaishuai Guo, Peng Xu, Jia Zheng, Liqiang Zheng, Jichun Tan. "Perinatal and maternal outcomes after frozen versus fresh embryo transfer cycles in women of advanced maternal age", European Journal of Obstetrics & Gynecology and Reproductive Biology, 2020

Publication

<1%

43

journals.lww.com

Internet Source

<1%

44

cjasn.asnjournals.org

Internet Source

<1%

45

Teena KJB Gamage, William Schierding, Daniel Hurley, Peter Tsai et al. "The role of DNA methylation in human trophoblast differentiation", Epigenetics, 2018

Publication

<1%

46

Fadl, Helena E., Susanne Gärdefors, Ragnhild Hjertberg, Eva Nord, Bengt Persson, Erik Schwarcz, Jan Åman, Ingrid K. Östlund, and Ulf S. B. Hanson. "Randomized controlled study in pregnancy on treatment of marked hyperglycemia that is short of overt diabetes",

<1%

Acta Obstetricia Et Gynecologica Scandinavica,
2015.

Publication

47

Submitted to Mahidol University

Student Paper

<1%

48

Gracia María Martín-Núñez, Elehazara Rubio-Martín, Rebeca Cabrera-Mulero, Gemma Rojo-Martínez et al. "Type 2 diabetes mellitus in relation to global LINE-1 DNA methylation in peripheral blood: A cohort study", Epigenetics, 2014

Publication

<1%

49

Burstyn, Igor, Stefan Kuhle, Alexander C. Allen, and Paul Veugeliers. "The Role of Maternal Smoking in Effect of Fetal Growth Restriction on Poor Scholastic Achievement in Elementary School", International Journal of Environmental Research and Public Health, 2012.

Publication

<1%

50

Shengde Wu. "Dynamic Epigenetic Changes Involved in Testicular Toxicity Induced by Di-2-(Ethylhexyl) Phthalate in Mice", Basic & Clinical Pharmacology & Toxicology, 02/2010

Publication

<1%

51

C. SCHILLER. "Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging", Alimentary

<1%

52

test-journals.seedmedicalpublishers.com

Internet Source

<1%

53

Nair, Jagadeesan, Roger W. Godschalk, Urmila Nair, Robert W. Owen, William E. Hull, and Helmut Bartsch. "Identification of 3,*N*⁴-Etheno-5-methyl-2'-deoxycytidine in Human DNA: A New Modified Nucleoside Which May Perturb Genome Methylation", *Chemical Research in Toxicology*, 2012.

Publication

<1%

54

Magana, A.A.. "High-performance liquid chromatography determination of 5-methyl-2'-deoxycytidine, 2'-deoxycytidine, and other deoxynucleosides and nucleosides in DNA digests", *Analytical Biochemistry*, 20080315

Publication

<1%

55

Huimin Ma. "Analysis of global DNA methylation levels in human blood using high-performance liquid chromatography/tandem electrospray ionization mass spectrometry", *European Journal of Mass Spectrometry*, 2009

Publication

<1%

56

Heewon Lee. "Pharmaceutical Applications of Liquid Chromatography Coupled with Mass Spectrometry (LC/MS)", *Journal of Liquid*

<1%

Chromatography & Related Technologies, 2007

Publication

57

Jill A. McKay, Long Xie, Sarah Harris, Yi K. Wong, Dianne Ford, John C. Mathers. "Blood as a surrogate marker for tissue-specific DNA methylation and changes due to folate depletion in post-partum female mice", *Molecular Nutrition & Food Research*, 2011

Publication

<1%

58

www.thieme-connect.com

Internet Source

<1%

59

Sharon Lewis. "Vitamin D deficiency and pregnancy: From preconception to birth", *Molecular Nutrition & Food Research*, 05/03/2010

Publication

<1%

60

Tina Rönn, Charlotte Ling. "DNA methylation as a diagnostic and therapeutic target in the battle against Type 2 diabetes", *Epigenomics*, 2015

Publication

<1%

61

Angela S Kelley, Yolanda R Smith, Vasantha Padmanabhan. "A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome", *The Journal of Clinical Endocrinology & Metabolism*, 2019

Publication

<1%

62

hdl.handle.net

Internet Source

<1%

63

Sharvari S. Deshpande, Nafisa H. Balasinor. "Placental Defects: An Epigenetic Perspective", *Reproductive Sciences*, 2018

Publication

<1%

64

Jana Nano, Eliana Portilla Fernandez, Jenna Troup, Mohsen Ghanbari, Oscar H. Franco, Taulant Muka. "Epigenetics of Diabetes in Humans", Elsevier BV, 2018

Publication

<1%

65

www.circumpolarhealthjournal.net

Internet Source

<1%

66

DeVries, Avery, and Donata Vercelli. "Early predictors of asthma and allergy in children : the role of epigenetics", *Current Opinion in Allergy and Clinical Immunology*, 2015.

Publication

<1%

67

Gogeneni, Himabindu, Nurcan Buduneli, Banu Ceyhan-Ozturk, Pinar Gumus, Aliye Akcali, Iris Zeller, Diane E. Renaud, David A. Scott, and Ozgun Ozcaka. "Increased infection with key periodontal pathogens during gestational diabetes mellitus", *Journal Of Clinical Periodontology*, 2015.

Publication

<1%

68

"Neuroepigenomics in Aging and Disease",
Springer Nature, 2017

Publication

<1%

69

Esben strup. "Embryo?maternal
communication: signalling before and during
placentation in cattle and pig", *Reproduction
Fertility and Development*, 2010

Publication

<1%

70

Fuminori Ito, Yuki Yamada, Aiko Shigemitsu,
Mika Akinishi, Hiroko Kaniwa, Ryuta Miyake,
Shoichiro Yamanaka, Hiroshi Kobayashi. "Role
of Oxidative Stress in Epigenetic Modification in
Endometriosis", *Reproductive Sciences*, 2017

Publication

<1%

71

T. Muka, J. Nano, T. Voortman, K.V.E. Braun et
al. "The role of global and regional DNA
methylation and histone modifications in
glycemic traits and type 2 diabetes: A
systematic review", *Nutrition, Metabolism and
Cardiovascular Diseases*, 2016

Publication

<1%

72

Mary Beth Terry, Lissette Delgado-Cruzata,
Neomi Vin-Raviv, Hui Chen Wu, Regina M.
Santella. "DNA methylation in white blood cells",
Epigenetics, 2014

Publication

<1%

Demetriou, Christiana A., Karin van Veldhoven,

73 Caroline Relton, Silvia Stringhini, Kyriacos Kyriacou, and Paolo Vineis. "Biological embedding of early life exposures and disease risk in humans: a role for DNA methylation", *European Journal of Clinical Investigation*, 2015. <1%
Publication

74 *Methods in Molecular Biology*, 2012. <1%
Publication

75 "Parental Obesity: Intergenerational Programming and Consequences", Springer Science and Business Media LLC, 2016 <1%
Publication

76 "The DNA, RNA, and Histone Methylomes", Springer Science and Business Media LLC, 2019 <1%
Publication

Exclude quotes Off Exclude matches < 4 words
Exclude bibliography On